

CITATION REPORT

List of articles citing

Complete replication of hepatitis C virus in cell culture

DOI: 10.1126/science.1114016
Science, 2005, 309, 623-6.

Source: <https://exaly.com/paper-pdf/39313909/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2039	Hepatitis C Virus Selectively Alters the Intracellular Localization of Desmosterol.		
2038	E2 of hepatitis C virus inhibits apoptosis. 2005 , 175, 8226-35		63
2037	Research Highlights. 2005 , 23, 831-831		
2036	Home-grown HCV. 2005 , 2, 565-565		
2035	Breakthrough for HCV research. 2005 , 4, 629-629		
2034	Unscrambling hepatitis C virus-host interactions. 2005 , 436, 930-2		185
2033	Unravelling hepatitis C virus replication from genome to function. 2005 , 436, 933-8		654
2032	Evasion of intracellular host defence by hepatitis C virus. 2005 , 436, 939-45		524
2031	Prospects for a vaccine against the hepatitis C virus. 2005 , 436, 961-6		270
2030	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. 2005 , 436, 967-72		795
2029	Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. 2005 , 437, 1167-72		1909
2028	Hepatitis C virus comes full circle: production of recombinant infectious virus in tissue culture. 2005 , 42, 1264-9		6
2027	Therapeutic RNA?. 2005 , 15, 349-50		2
2026	Breakthrough for HCV research. 2005 , 3, 585-585		1
2025	Quantitative analysis of the hepatitis C virus replication complex. 2005 , 79, 13594-605		235
2024	Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. 2005 , 43, 5679-84		86
2023	Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. 2005 , 79, 15525-36		63

2022	Interfering with interferons: Hepatitis C virus counters innate immunity. 2005 , 102, 17539-40	19
2021	Efficient hepatitis C virus cell culture system: what a difference the host cell makes. 2005 , 102, 9739-40	83
2020	Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. 2005 , 280, 39802-8	52
2019	Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. 2005 , 79, 13963-73	134
2018	Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. 2005 , 102, 18544-9	223
2017	Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. 2005 , 86, 3189-3199	45
2016	Mutagenic effects of ribavirin in vivo. 2005 , 43, 553-5	13
2015	Opiate abuse and viral replication in hepatitis C. 2005 , 167, 1189-91	7
2014	Salient molecular features of hepatitis C virus revealed. 2005 , 13, 528-34	7
2013	Molecular virology of the hepatitis C virus: implication for novel therapies. 2005 , 9, 353-69, v	5
2012	Replication of a hepatitis C virus replicon clone in mouse cells. 2006 , 3, 89	77
2011	Analysis of in vitro replicated human hepatitis C virus (HCV) for the determination of genotypes and quasispecies. 2006 , 3, 81	5
2010	Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. 2006 , 3, 56	67
2009	Pharmacotherapy for a Phantom Menace. 2006 , 4, 8-13	
2008	Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. 2006 , 15, 405-16	39
2007	Molecular virology of the hepatitis C virus: implication for novel therapies. 2006 , 20, 81-98	1
2006	Replication and Pathogenesis of Hepatitis C Virus. 2006 , 125-147	1
2005	Hepatitis B Virus and Hepatitis C Virus: Molecular Biology and Diagnosis. 2006 , 13, 109-139	

2004	Inhibition of the interferon antiviral response by hepatitis C virus. 2006 , 2, 49-58	2
2003	Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. 2006 , 80, 10579-90	150
2002	Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. 2006 , 103, 2310-5	317
2001	Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. 2006 , 80, 8695-704	204
2000	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents. 2006 , 49, 2621-7	63
1999	Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. 2006 , 169, 200-8	84
1998	Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. 2006 , 281, 3909-17	105
1997	High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. 2006 , 281, 18285-95	169
1996	Hepatitis C virus: virology and experimental systems. 2006 , 10, 773-91	4
1995	Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. 2006 , 131, 1887-98	484
1994	Situaci3n actual. Perspectivas y vacunaci3n. 2006 , 29, 96-100	
1993	2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. 2006 , 49, 1693-705	81
1992	Cell culture and infection system for hepatitis C virus. 2006 , 1, 2334-9	160
1991	Hepatitis C vaccines. 2006 , 3, 203-209	
1990	Hepatitis C virus entry: potential receptors and their biological functions. 2006 , 87, 1075-1084	150
1989	Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. 2006 , 80, 404-11	108
1988	Characterization of HCV-like particles produced in a human hepatoma cell line by a recombinant baculovirus. 2006 , 340, 200-8	35
1987	Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. 2006 , 346, 1163-72	15

1986	Novel approaches for therapy of chronic hepatitis C. 2006 , 36, 87-94	19
1985	The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 2006 , 44, 411-21	67
1984	Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. 2006 , 9, 416-22	63
1983	Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. 2006 , 22, 561-9	320
1982	Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. 2006 , 122, 1-10	39
1981	Mutations of the Hepatitis C virus protein NS4B on either side of the ER membrane affect the efficiency of subgenomic replicons. 2006 , 121, 169-78	25
1980	Tailoring immunosuppressants to hepatitis C virus-infected transplant patients. 2006 , 20, 157-164	
1979	Molecular virology of hepatitis C virus (HCV): 2006 update. 2006 , 3, 29-34	58
1978	. 2006 ,	59
1977	Hepatitis C. 2006 ,	
1976	A novel virus culture system for hepatitis C virus. 2006 , 1, 519-525	1
1975	Resistance of hepatitis C virus to the host antiviral response. 2006 , 1, 89-98	3
1974	Flaviviruses. 2006 , 274-303	
1973	Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. 2006 , 6, 31-41	41
1972	Current world literature. 2006 , 1, 449-69	
1971	Liver and biliary tract disorders. 2006 , 22, 193-7	2
1970	Current World Literature. 2006 , 19, 493-531	
1969	The hepatic transcriptome in human liver disease. 2006 , 5, 6	21

1968	Mechanisms of action of ribavirin against distinct viruses. 2006 , 16, 37-48	353
1967	Drug abuse, innate immunity and hepatitis C virus. 2006 , 16, 311-27	19
1966	Progress with hepatitis C. 2006 , 16, 205-7	
1965	Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. 2006 , 8, 1134-46	81
1964	How does hepatitis C virus enter cells?. 2006 , 273, 3871-85	23
1963	Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. 2007 , 147, 241-8	35
1962	Hepatocellular carcinoma pathogenesis: from genes to environment. 2006 , 6, 674-87	1567
1961	Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. 2006 , 25, 5015-25	195
1960	The phantom menace. 2006 , 7, 14-7	3
1959	Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. 2006 , 13, 563-75	74
1958	RNA interference-mediated prevention and therapy for hepatocellular carcinoma. 2006 , 25, 3857-65	26
1957	Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds. 2006 , 16, 4987-93	75
1956	Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: a new class of pestivirus inhibitors. 2006 , 16, 5345-9	27
1955	Simultaneous quantitative measurement of luciferase reporter activity and cell number in two- and three-dimensional cultures of hepatitis C virus replicons. 2006 , 350, 239-48	16
1954	Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. 2006 , 80, 3332-40	32
1953	A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase. 2006 , 80, 149-60	72
1952	Assembly of HCV E1 and E2 glycoproteins into coronavirus VLPs. 2006 , 151, 2085-94	1
1951	Understanding the precise function of interferon regulatory factor 3 in hepatitis C virus replication will lead to a new strategy for therapy. 2006 , 41, 814-5	

1950	Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. <i>Virology</i> , 2006 , 351, 381-92	3.6	37
1949	Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. <i>Virology</i> , 2006 , 355, 192-202	3.6	14
1948	A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. 2006 , 69, 129-41		102
1947	Recent development of therapeutics for chronic HCV infection. 2006 , 71, 351-62		61
1946	Selective inhibitors of hepatitis C virus replication. 2006 , 71, 363-71		46
1945	Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease. 2006 , 72, 1477-84		25
1944	[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. 2006 , 30, 1281-95		3
1943	Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection. 2006 , 2, 38-45		2
1942	Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. 2006 , 36, 919-29		39
1941	Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. 2006 , 43, 257-65		61
1940	Therapy of hepatitis C: from empiricism to eradication. 2006 , 43, S207-20		142
1939	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. 2006 , 43, 592-601		132
1938	A novel function for a micro RNA: negative regulators can do positive for the hepatitis C virus. 2006 , 43, 612-5		9
1937	The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. 2006 , 43, 761-70		247
1936	Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. 2006 , 43, 932-42		108
1935	Host cell responses induced by hepatitis C virus binding. 2006 , 43, 1326-36		19
1934	HCV and lipoproteins: is oxLDL an Achilles' heel of the Trojan horse?. 2006 , 43, 903-5		5
1933	Different anti-HCV profiles of statins and their potential for combination therapy with interferon. 2006 , 44, 117-25		261

1932	Hepatitis C virus entry: molecular biology and clinical implications. 2006 , 44, 527-35	102
1931	Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. 2006 , 44, 1626-34	75
1930	A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. 2006 , 78, 1423-8	79
1929	Interferon action and the double-stranded RNA-dependent enzymes ADAR1 adenosine deaminase and PKR protein kinase. 2006 , 81, 369-434	74
1928	Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. 2006 , 80, 1181-90	47
1927	Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. 2006 , 80, 298-308	9
1926	Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. 2006 , 80, 7569-77	124
1925	HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins. 2006 , 6, 393-8	7
1924	The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. 2006 , 20, 735-7	125
1923	Diverse CD81 proteins support hepatitis C virus infection. 2006 , 80, 11331-42	128
1922	De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. 2006 , 87, 3577-3586	38
1921	Lipid membrane; a novel target for viral and bacterial pathogens. 2006 , 7, 1615-21	29
1920	A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo. 2006 , 103, 3500-1	22
1919	Structural determinants that target the hepatitis C virus core protein to lipid droplets. 2006 , 281, 22236-22247	172
1918	Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. 2006 , 80, 1734-41	318
1917	Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. 2006 , 80, 7364-74	88
1916	In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. 2007 , 59, 51-8	16
1915	Relationships between hepatitis C virus replication and CXCL-8 production in vitro. 2006 , 80, 7885-93	32

1914	Novel robust hepatitis C virus mouse efficacy model. 2006 , 50, 3260-8	29
1913	VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. 2006 , 50, 1813-22	177
1912	Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly. 2006 , 87, 855-860	43
1911	Hepatitis C virus infection, cryoglobulinaemia, and beyond. 2007 , 46, 572-8	75
1910	The hepatitis C virus RNA 3'-untranslated region strongly enhances translation directed by the internal ribosome entry site. 2006 , 80, 11579-88	117
1909	Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system. 2006 , 50, 3984-91	8
1908	SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. 2006 , 50, 1013-20	269
1907	Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. 2006 , 80, 5308-20	343
1906	The NS5A protein of bovine viral diarrhea virus contains an essential zinc-binding site similar to that of the hepatitis C virus NS5A protein. 2006 , 80, 7450-8	39
1905	In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. 2006 , 194, 1058-67	27
1904	Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay. 2006 , 80, 1817-25	38
1903	Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. 2006 , 80, 2832-41	162
1902	Generation of infectious hepatitis C virus in immortalized human hepatocytes. 2006 , 80, 4633-9	81
1901	Analysis of hepatitis C virus RNA dimerization and core-RNA interactions. 2006 , 34, 2618-33	68
1900	Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. 2006 , 103, 3805-9	375
1899	Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. 2006 , 87, 2983-2991	85
1898	Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. 2006 , 80, 10253-7	81
1897	Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein. 2006 , 80, 11265-73	45

1896	Persistent hepatitis C virus infection in vitro: coevolution of virus and host. 2006 , 80, 11082-93	218
1895	Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. 2006 , 80, 11074-81	199
1894	A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. 2006 , 80, 7844-53	114
1893	From structure to function: new insights into hepatitis C virus RNA replication. 2006 , 281, 9833-6	153
1892	Targets of emerging therapies for viral hepatitis B and C. 2006 , 10, 833-50	6
1891	Signal peptide peptidase cleavage of GB virus B core protein is required for productive infection in vivo. 2006 , 281, 29221-7	37
1890	Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. 2006 , 281, 25177-83	132
1889	Signal peptide peptidase-catalyzed cleavage of hepatitis C virus core protein is dispensable for virus budding but destabilizes the viral capsid. 2006 , 281, 27679-92	33
1888	Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. 2006 , 281, 37057-68	108
1887	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. 2006 , 103, 7408-13	600
1886	Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. 2006 , 87, 323-327	31
1885	Diverse effects of cyclosporine on hepatitis C virus strain replication. 2006 , 80, 4510-20	131
1884	Hepatitis C virus entry depends on clathrin-mediated endocytosis. 2006 , 80, 6964-72	436
1883	Implications of the HCV subgenome discovery for viral pathogenesis, persistence and proliferation. 2006 , 1, 425-433	1
1882	Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. 2006 , 80, 4940-8	77
1881	Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. 2006 , 103, 8499-504	111
1880	Hepatitis C virus: new advances trap an age-old killer. 2006 , 1, 703-708	
1879	Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. 2007 , 81, 13783-93	348

1878	Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. 2007 , 104, 16269-74	115
1877	Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. 2007 , 81, 12465-71	165
1876	Superinfection exclusion in cells infected with hepatitis C virus. 2007 , 81, 3693-703	119
1875	Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. 2007 , 51, 3756-9	17
1874	Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. 2007 , 81, 8374-83	358
1873	The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. 2007 , 282, 37158-69	203
1872	The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. 2007 , 282, 32357-69	71
1871	Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. 2007 , 282, 32765-72	49
1870	An influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesis. 2007 , 104, 18235-40	69
1869	Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. 2007 , 51, 503-9	92
1868	E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. 2007 , 81, 1174-85	92
1867	Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1. 2007 , 88, 1144-1148	74
1866	Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. 2007 , 81, 5829-40	83
1865	Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. 2007 , 81, 3933-41	58
1864	Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. 2007 , 204, 2423-37	97
1863	Evidence for a functional RNA element in the hepatitis C virus core gene. 2007 , 104, 2879-84	106
1862	Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. <i>PLoS Pathogens</i> , 2007 , 3, e103	7.6 266
1861	The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. 2007 , 81, 8905-18	85

1860	Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. <i>PLoS Pathogens</i> , 2007 , 3, 1335-47	7.6	107
1859	Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. <i>PLoS Pathogens</i> , 2007 , 3, e108	7.6	108
1858	Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. 2007 , 7, 1302-29		103
1857	HCV requires a tight junction-associated protein for cell entry. 2007 , 2, 335-338		1
1856	Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. 2007 , 81, 4591-603		174
1855	Emerging strategies for pegylated interferon combination therapy. 2007 , 4 Suppl 1, S17-21		10
1854	Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. 2007 , 27, 13-27		48
1853	Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection. 2007 , 94, 215-44		32
1852	Regulation of interferon production by RIG-I and LGP2: a lesson in self-control. 2007 , 2007, pe20		25
1851	Cellular cofactors affecting hepatitis C virus infection and replication. 2007 , 104, 12884-9		478
1850	Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents. 2007 , 18, 169-89		9
1849	Morphine inhibits intrahepatic interferon- alpha expression and enhances complete hepatitis C virus replication. 2007 , 196, 719-30		29
1848	Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. 2007 , 81, 13168-79		138
1847	High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. 2007 , 81, 8063-71		128
1846	Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries. 2007 , 88, 1149-1162		28
1845	Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. 2007 , 51, 2016-27		73
1844	The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. 2007 , 81, 8030-40		53
1843	Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. 2007 , 81, 669-76		71

1842	Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. 2007 , 81, 629-38	240
1841	Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. 2007 , 81, 3162-9	126
1840	Production of infectious hepatitis C virus of various genotypes in cell cultures. 2007 , 81, 4405-11	90
1839	A chimeric GB virus B encoding the hepatitis C virus hypervariable region 1 is infectious in vivo. 2007 , 88, 895-902	25
1838	Norwalk virus RNA is infectious in mammalian cells. 2007 , 81, 12238-48	124
1837	Monitoring the antiviral effect of alpha interferon on individual cells. 2007 , 81, 8814-20	35
1836	Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. 2007 , 81, 1043-7	76
1835	A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. 2007 , 81, 11096-105	63
1834	GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS. 2007 , 81, 964-76	120
1833	Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. 2007 , 81, 10220-31	99
1832	Human serum amyloid A protein inhibits hepatitis C virus entry into cells. 2007 , 81, 6128-33	57
1831	Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. 2007 , 81, 750-60	84
1830	Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. 2007 , 81, 8953-66	135
1829	Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. 2007 , 88, 2204-2213	206
1828	Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. 2007 , 81, 374-83	218
1827	Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. 2007 , 51, 95-102	29
1826	Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. 2007 , 81, 8601-12	63
1825	Studying hepatitis C virus: making the best of a bad virus. 2007 , 81, 8853-67	113

1824	Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. 2007 , 88, 1133-1143	49
1823	Hepatitis C virus coinfection and superinfection. 2007 , 195, 519-24	54
1822	Integration of technologies for hepatic tissue engineering. 2007 , 103, 309-29	60
1821	Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. 2007 , 88, 134-142	36
1820	Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. 2007 , 81, 9633-40	54
1819	CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. 2007 , 81, 5036-45	108
1818	Impact of human immune deficiency virus infection on hepatitis C virus infection and replication. 2007 , 5, 55-67	10
1817	Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. 2007 , 104, 8449-54	108
1816	Hepatitis C virus host cell interactions uncovered. 2007 , 104, 13215-6	4
1815	TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. 2007 , 282, 36354-61	92
1814	Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. 2007 , 81, 8122-30	221
1813	The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. 2007 , 81, 588-98	185
1812	Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. 2007 , 81, 2372-81	70
1811	Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. 2007 , 81, 8752-65	144
1810	Lifestyle-related diseases of the digestive system: a new in vitro model of hepatitis C virion production: application of basic research on hepatitis C virus to clinical medicine. 2007 , 105, 138-44	4
1809	Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. 2007 , 105, 145-50	49
1808	What does the future hold for viral gene therapy?. 2007 , 2, 543-547	
1807	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. 2007 , 25, 7773-84	70

1806	Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins. 2007 , 123, 40-9	2
1805	Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon. 2007 , 125, 109-13	10
1804	Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. 2007 , 125, 88-97	27
1803	Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication. 2007 , 125, 162-8	2
1802	Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. 2007 , 127, 195-207	89
1801	Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from <i>Fructus Ligustri Lucidi</i> . 2007 , 128, 9-17	20
1800	The NS5A protein of hepatitis C virus represses gene expression of hRPB10alpha, a common subunit of host RNA polymerases, through interferon regulatory factor-1 binding site. 2007 , 129, 155-65	1
1799	Subversion of innate host antiviral strategies by the hepatitis C virus. 2007 , 462, 254-65	32
1798	Helper virus-independent trans-replication of hepatitis C virus-derived minigenome. 2007 , 352, 170-6	3
1797	Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. 2007 , 46, 26-36	68
1796	Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line. 2007 , 46, 53-9	6
1795	The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. 2007 , 46, 411-9	227
1794	Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions?. 2007 , 46, 1-5	12
1793	In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. 2007 , 46, 355-8	12
1792	Immunological techniques in viral hepatitis. 2007 , 46, 508-20	39
1791	Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A. 2007 , 28, 7-18	17
1790	Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81. 2007 , 68, 601-4	11
1789	Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. 2007 , 170, 478-89	81

1788	Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame. 2007 , 171, 1831-46	23
1787	Potential role of RNAi in the treatment of HCV infection. 2007 , 5, 823-31	7
1786	An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. 2007 , 37, 433-43	20
1785	Evaluation of chemical labeling strategies for monitoring HCV RNA using vibrational microscopy. 2007 , 5, 2380-9	7
1784	A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. 2007 , 4, 35	16
1783	Viral Hepatitis. 819-956	
1782	Liver Immunology. 2007 ,	4
1781	A highly efficient and robust in vitro translation system for expression of picornavirus and hepatitis C virus RNA genomes. 2007 , 429, 53-82	12
1780	p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. 2007 , 282, 11836-48	47
1779	T and B cells in hepatitis C virus control: what they do and when they fail. 2007 , 132, 801-5	5
1778	Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. 2007 , 132, 1925-36	163
1777	Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. 2007 , 133, 1614-26	159
1776	Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. 2007 , 133, 1649-59	93
1775	[Pathogenesis of hepatitis C virus]. 2007 , 57, 141-9	3
1774	[A new system for the culture of hepatitis C virus]. 2007 , 23, 588-9	0
1773	The interferon inducing pathways and the hepatitis C virus. 2007 , 13, 2446-54	37
1772	Hepatitis C virus proteins. 2007 , 13, 2406-15	113
1771	A specific viral cause of multiple sclerosis: one virus, one disease. 2007 , 61, 514-23	43

1770	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. 2007 , 46, 330-8	117
1769	Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. 2008 , 47, 17-24	277
1768	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. 2007 , 46, 1722-31	209
1767	Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. 2008 , 47, 385-95	89
1766	Hepatitis C virus receptor expression in normal and diseased liver tissue. 2008 , 47, 418-27	82
1765	Hepatitis C virus living off the fat of the land. 2008 , 47, 343-5	2
1764	Interleukin-22, interleukin-17, and other cytokines: a wall is coming down. 2008 , 47, 345-8	5
1763	Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon. 2007 , 27, 353-73	33
1762	The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. 2007 , 79, 714-23	56
1761	Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression. 2007 , 79, 1120-7	14
1760	Host factors involved in the replication of hepatitis C virus. 2007 , 17, 343-54	33
1759	The lipid droplet is an important organelle for hepatitis C virus production. 2007 , 9, 1089-97	965
1758	Structural and mechanistic insights into hepatitis C viral translation initiation. 2007 , 5, 29-38	176
1757	Replication of hepatitis C virus. 2007 , 5, 453-63	1049
1756	Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. 2007 , 85, 24-32	46
1755	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. 2007 , 446, 801-5	970
1754	Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane. 2007 , 9, 1014-27	40
1753	Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. 2007 , 9, 2445-56	68

1752	In vitro replication models for the hepatitis C virus. 2007 , 14, 2-10		16
1751	Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. 2007 , 14, 447-59		28
1750	Hepatitis C virus infection: in vivo and in vitro models. 2007 , 14 Suppl 1, 64-7		18
1749	The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. 2007 , 14 Suppl 1, 68-76		12
1748	Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. 2007 , 14 Suppl 1, 97-103		33
1747	Hepatitis C virus core protein, lipid droplets and steatosis. 2008 , 15, 157-64		53
1746	Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle. 2007 , 274, 4705-18		4
1745	Alternative invasion pathways for Plasmodium berghei sporozoites. 2007 , 37, 173-82		48
1744	Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. 2007 , 73, 40-9		32
1743	Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. 2007 , 76, 48-58		68
1742	A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro. <i>Virology</i> , 2007 , 360, 17-26	3.6	17
1741	Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. <i>Virology</i> , 2007 , 361, 161-73	3.6	61
1740	Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?. <i>Virology</i> , 2007 , 364, 1-9	3.6	130
1739	Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. <i>Virology</i> , 2007 , 366, 40-50	3.6	58
1738	Packaged replicons of bovine viral diarrhea virus are capable of inducing a protective immune response. <i>Virology</i> , 2007 , 366, 377-86	3.6	18
1737	Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. <i>Virology</i> , 2007 , 367, 126-34	3.6	46
1736	Selection of an optimal RNA transfection reagent and comparison to electroporation for the delivery of viral RNA. 2007 , 145, 14-21		18
1735	L'Épâtite C en 2007 « Des progrès. Peut-on mieux faire? ». 2007 , 31, 3-6		3

1734	The hepatitis C virus life cycle as a target for new antiviral therapies. 2007 , 132, 1979-98	254
1733	Modulation of host metabolism as a target of new antivirals. 2007 , 59, 1277-89	31
1732	Therapeutic application of RNA interference for hepatitis C virus. 2007 , 59, 1263-76	33
1731	Hepatitis C viral life cycle. 2007 , 59, 1200-12	103
1730	Evaluation systems for anti-HCV drugs. 2007 , 59, 1213-21	14
1729	Interferon-based therapy of hepatitis C. 2007 , 59, 1222-41	68
1728	HCV research and anti-HCV drug discovery: toward the next generation. 2007 , 59, 1196-9	6
1727	Hepatitis C virus infection--pathobiology and implications for new therapeutic options. 2007 , 52, 857-75	6
1726	Transient and stable expression of the HCV envelope glycoproteins in cell lines and primary hepatocytes transduced with a recombinant baculovirus. 2007 , 152, 329-43	11
1725	Molecular biology of hepatitis C virus. 2007 , 42, 411-23	94
1724	Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. 2007 , 42, 424-32	7
1723	Specific targeted antiviral therapy for hepatitis C. 2007 , 9, 5-13	17
1722	Hepatitis C virus entry into host cells. 2008 , 65, 100-12	111
1721	Novel therapies in hepatitis B and C. 2008 , 10, 81-90	6
1720	Virus-host interactions during hepatitis C virus entry ¶implications for pathogenesis and novel treatment approaches. 2008 , 23, 124-131	1
1719	Baculovirus mediated production of infectious hepatitis C virus in human hepatoma cells stably expressing T7 RNA polymerase. 2008 , 40, 186-94	4
1718	Hepatitis C virus budding at lipid droplet-associated ER membrane visualized by 3D electron microscopy. 2008 , 130, 561-6	48
1717	Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays. 2008 , 80, 72-9	24

1716	The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity. 2008 , 3, 1508-15	19
1715	Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. 2008 , 48, 16-27	62
1714	Host neutralizing responses and pathogenesis of hepatitis C virus infection. 2008 , 48, 299-307	42
1713	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. 2008 , 48, 732-40	51
1712	Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. 2008 , 48, 1054-61	278
1711	Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. 2008 , 48, 1761-8	182
1710	Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. 2008 , 48, 1843-50	205
1709	Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. 2008 , 48, 1779-90	99
1708	Activity of Mannich bases of 7-hydroxycoumarin against Flaviviridae. 2008 , 16, 2591-605	46
1707	Resistance mechanisms in HCV: from evolution to intervention. 2008 , 6, 463-78	14
1706	Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. 2008 , 52, 1901-11	22
1705	Putative hepatitis C virus cell receptors. 2008 , 2, 258-266	0
1704	Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. 2008 , 9, 1268-82	179
1703	Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. 2008 , 26, 1019-27	190
1702	Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. 2008 , 6, 699-708	170
1701	Viral hepatocarcinogenesis: from infection to cancer. 2008 , 28, 175-88	83
1700	Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. 2008 , 10, 606-17	69
1699	Early steps of the hepatitis C virus life cycle. 2008 , 10, 821-7	95

1698	HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?. 2008 , 15, 323-30		71
1697	Natural killer cells suppress full cycle HCV infection of human hepatocytes. 2008 , 15, 855-64		41
1696	Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor. 2008 , 15, 865-70		11
1695	Primary hepatocytes as targets for hepatitis C virus replication. 2008 , 15, 849-54		25
1694	Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. <i>Virology</i> , 2008 , 371, 71-85	3.6	36
1693	Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. <i>Virology</i> , 2008 , 376, 397-407	3.6	49
1692	Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones. 2008 , 9, 309		13
1691	Inhibition of hepatitis C virus RNA replicons by peptide aptamers. 2008 , 77, 195-205		17
1690	Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. 2008 , 80, 280-7		17
1689	The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. 2008 , 80, 231-8		105
1688	[Neutralizing antibodies in hepatitis C virus infection]. 2008 , 32, 491-8		1
1687	Modulation of signaling pathways by RNA virus capsid proteins. 2008 , 20, 1227-36		17
1686	Dynamic behavior of hepatitis C virus quasispecies in a long-term culture of the three-dimensional radial-flow bioreactor system. 2008 , 148, 174-81		8
1685	Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. 2008 , 71, 51-133		79
1684	Drugs in development for hepatitis C. 2008 , 68, 1347-59		13
1683	Hepatitis C virus (HCV): a review of immunological aspects. 2008 , 27, 497-517		36
1682	Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. 2008 , 135, 1719-1728.e1		62
1681	Flaviviruses: General Features. 2008 , 241-252		1

1680	Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. 2008 , 317, 1-38	21
1679	Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. 2008 , 5, 102	13
1678	Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. 2008 , 5, 46	52
1677	Hepatitis C Virus. 2008 , 367-374	1
1676	Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. 2008 , 82, 3466-79	71
1675	RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle. 2008 , 48, 523-5	15
1674	Mouse models for the study of HCV infection and virus-host interactions. 2008 , 49, 134-42	47
1673	Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo. 2008 , 49, 908-15	17
1672	Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. 2008 , 49, 1069-78	18
1671	Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. 2008 , 26, 5527-5534	18
1670	A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. 2008 , 131, 260-70	17
1669	Bovine viral diarrhea virus is a suitable viral vector for stable expression of heterologous gene when inserted in between N(pro) and C genes. 2008 , 138, 97-104	17
1668	Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. 2008 , 371, 446-50	21
1667	Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L. 2008 , 372, 157-61	5
1666	A recombinant replication-competent hepatitis C virus expressing Azami-Green, a bright green-emitting fluorescent protein, suitable for visualization of infected cells. 2008 , 377, 7-11	6
1665	Characterization of infectious hepatitis C virus from liver-derived cell lines. 2008 , 377, 747-51	8
1664	Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. 2008 , 38, 909-18	18
1663	Hepatitis C virus entry and neutralization. 2008 , 12, 693-712, x	40

1662	Novel hepatitis C drugs in current trials. 2008 , 12, 529-55, viii	17
1661	Management strategies for hepatitis C virus infection in children. 2008 , 10, 357-65	16
1660	Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. 2008 , 82, 1047-52	110
1659	Hepatitis C virus entry. 2008 , 283, 3689-93	73
1658	RNA unwinding activity of the hepatitis C virus NS3 helicase is modulated by the NS5B polymerase. 2008 , 47, 1126-35	34
1657	Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. 2008 , 283, 16850-9	72
1656	Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. 2008 , 82, 10375-85	136
1655	NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. 2008 , 82, 7624-39	172
1654	Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. 2008 , 82, 7964-76	291
1653	Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. 2008 , 82, 7034-46	120
1652	Iminosugars in combination with interferon and ribavirin permanently eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells. 2008 , 52, 1820-8	16
1651	Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. 2008 , 82, 11503-15	78
1650	Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. 2008 , 82, 5269-78	200
1649	The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. 2008 , 82, 3555-60	159
1648	A hepatitis C virus cis-acting replication element forms a long-range RNA-RNA interaction with upstream RNA sequences in NS5B. 2008 , 82, 9008-22	91
1647	Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. 2008 , 82, 1073-83	171
1646	Proteome analysis identifies the role of heat stress in production of progeny HCV in Huh7 cells harboring intact HCV. 2008 , 51, 196-202	1
1645	A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. 2008 , 82, 3480-9	51

1644	Hepatitis C virus genotype 1a growth and induction of autophagy. 2008 , 82, 2241-9	188
1643	Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. 2008 , 29, 5-16	23
1642	Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. 2008 , 89, 1587-1592	15
1641	Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein tyrosine kinase Syk. 2008 , 89, 1231-1242	23
1640	Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. 2008 , 82, 8797-811	81
1639	Apolipoprotein c1 association with hepatitis C virus. 2008 , 82, 9647-56	111
1638	Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. 2008 , 105, 997-1002	156
1637	Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1. 2008 , 89, 1569-1578	26
1636	Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. 2008 , 283, 28546-62	124
1635	Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. 2008 , 181, 4926-35	62
1634	Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. 2008 , 283, 8643-53	86
1633	Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. 2008 , 82, 3438-51	53
1632	A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. 2008 , 105, 3088-93	117
1631	The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma. 2008 , 1, 167-175	10
1630	Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication. 2008 , 52, 1419-29	7
1629	High-resolution functional profiling of hepatitis C virus genome. <i>PLoS Pathogens</i> , 2008 , 4, e1000182	7.6 42
1628	Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. <i>PLoS Pathogens</i> , 2008 , 4, e1000143	7.6 69
1627	Pathogenesis and Clinical Practice in Gastroenterology. 2008 ,	

1626	Hepatitis C virus: the growing challenge. 2009 , 89, 153-67		8
1625	Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. <i>PLoS Pathogens</i> , 2008 , 4, e1000010	7.6	61
1624	Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. <i>PLoS Pathogens</i> , 2008 , 4, e1000032	7.6	313
1623	Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. <i>PLoS Pathogens</i> , 2008 , 4, e1000035	7.6	363
1622	Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. 2008 , 82, 8349-61		87
1621	Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. 2008 , 105, 4370-5		143
1620	Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. 2008 , 82, 12020-9		137
1619	Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation. 2008 , 283, 33893-901		29
1618	Antimicrobial Resistance and Implications for the Twenty-First Century. 2008 ,		3
1617	Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. 2008 , 52, 666-74		17
1616	Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication. 2008 , 82, 2631-41		41
1615	Brett Lindenbach: deconstructing and reconstructing hepatitis C. Interview by Ruth Williams. 2008 , 183, 754-5		
1614	3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U). 2008 , 82, 184-95		100
1613	How does interferon inhibit HCV cell entry?. 2008 , 57, 573-4		
1612	Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. 2008 , 82, 966-73		131
1611	CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. 2008 , 82, 8316-29		144
1610	Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. 2008 , 198, 1756-65		93
1609	CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. 2008 , 82, 5007-20		154

1608	Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. 2008 , 82, 569-74	121
1607	Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. 2008 , 52, 3327-38	103
1606	A dynamic view of hepatitis C virus replication complexes. 2008 , 82, 10519-31	115
1605	Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. 2008 , 47, 627-33	47
1604	Effect of cell polarization on hepatitis C virus entry. 2008 , 82, 461-70	98
1603	Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. 2008 , 82, 2182-95	143
1602	New developments in the discovery of agents to treat hepatitis C. 2008 , 8, 533-62	31
1601	Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. 2008 , 89, 653-659	121
1600	Human Antibody Therapeutics for Viral Disease. 2008 ,	2
1599	Hepatitis C virus entry: possible targets for therapy. 2008 , 57, 1728-37	27
1598	HCV and autoimmunity. 2008 , 14, 1678-85	56
1597	The Impact of Rapid Evolution of Hepatitis Viruses. 2008 , 303-349	7
1596	[Involvement of nonstructural protein 5A and lipids on production of hepatitis C virus particles]. 2008 , 58, 199-205	2
1595	Intrahepatic expression of interferon alpha & interferon alpha receptor m-RNA can be used as predictors to interferon response in HCV and HCC patients. 2008 , 14,	
1594	Hepatitis C Virus Genetics and the Discovery of Mechanism-Based Inhibitors of the NS3/4A Protease and NS5B Polymerase. 2008 , 63-93	
1593	Proteomics of viruses. 2008 , 309-343	
1592	Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. 2009 , 14, 3274-85	34
1591	Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. 2009 , 1, 144-65	9

1590	Transfusion-Transmitted Hepatitis. 718-745	1
1589	HCV animal models: a journey of more than 30 years. 2009 , 1, 222-40	13
1588	Adaptive immunity to hepatitis C virus. 2009 , 1, 276-97	1
1587	Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. 2009 , 4, e8254	56
1586	Hepatitis C. 2009 , 413-440	1
1585	Development of hepatitis C virus vaccines: challenges and progress. 2009 , 8, 333-45	70
1584	New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. 2009 , 58, 1644-53	65
1583	Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. 2009 , 4, 277-293	43
1582	Peptide inhibitors of hepatitis C virus core oligomerization and virus production. 2009 , 90, 1319-1328	22
1581	The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. 2009 , 83, 2163-77	122
1580	Lack of adaptation of chimeric GB virus B/hepatitis C virus in the marmoset model: possible effects of bottleneck. 2009 , 83, 8062-75	12
1579	Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. 2009 , 83, 5693-707	28
1578	Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. 2009 , 106, 7537-41	117
1577	Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. 2009 , 83, 11078-89	47
1576	Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. 2009 , 83, 9824-34	159
1575	Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. 2009 , 83, 10058-74	171
1574	Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. 2009 , 53, 4311-9	32
1573	Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. 2009 , 83, 5477-84	59

1572	Determinants of the hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. 2009 , 83, 12702-13	45
1571	Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. 2009 , 83, 6149-60	75
1570	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. 2009 , 106, 16410-5	301
1569	Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein. 2009 , 83, 5137-47	37
1568	Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA. 2009 , 90, 833-842	22
1567	Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. 2009 , 53, 4825-34	21
1566	Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. 2009 , 83, 6554-65	142
1565	Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. 2009 , 83, 8379-95	109
1564	SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. 2009 , 47, 1217-25	15
1563	Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. 2009 , 1, 446-54	23
1562	HCV entry and neutralizing antibodies: lessons from viral variants. 2009 , 4, 511-7	6
1561	Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. 2009 , 8, 856-65	55
1560	Conservation of hydrophobicity within viral envelope glycoproteins reveals a putative hepatitis C virus fusion peptide. 2009 , 16, 815-22	4
1559	Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. 2009 , 20, 47-54	11
1558	Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. <i>PLoS Pathogens</i> , 2009 , 5, e1000546	7.6 216
1557	RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. <i>PLoS Pathogens</i> , 2009 , 5, e1000702	7.6 134
1556	Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. <i>PLoS Pathogens</i> , 2009 , 5, e1000269	7.6 101
1555	Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. 2009 , 23, 3780-9	130

1554	HCV has transforming potential to retrovirus: an ultrastructure hypothesis. 2009 , 33, 21-7		3
1553	Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions. 2009 , 83, 9923-39		26
1552	Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. 2009 , 284, 17657-67		74
1551	The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1. 2009 , 83, 9993-10006		24
1550	Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. <i>PLoS Pathogens</i> , 2009 , 5, e1000403	7.6	84
1549	Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. 2009 , 90, 1681-1691		44
1548	Naturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles. 2009 , 83, 9079-93		33
1547	Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. 2009 , 83, 11926-39		65
1546	Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. 2009 , 83, 6211-21		104
1545	Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. 2009 , 83, 4174-84		128
1544	Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. 2009 , 83, 3104-14		36
1543	Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. 2009 , 90, 1055-1070		162
1542	Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. 2009 , 83, 12407-14		36
1541	Hepatitis C virus infection of T cells inhibits proliferation and enhances fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6. 2009 , 199, 726-36		34
1540	Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. 2009 , 83, 7970-81		60
1539	Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells. 2009 , 53, 728-34		18
1538	Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. 2009 , 106, 13517-22		112
1537	Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. 2009 , 83, 11682-93		63

1536	Cellular models for the screening and development of anti-hepatitis C virus agents. 2009 , 124, 1-22		20
1535	Rapid synchronization of hepatitis C virus infection by magnetic adsorption. 2009 , 157, 69-79		7
1534	Persistent replication of the GBV-C subgenomic replicons in Huh7 cells. 2009 , 157, 168-74		2
1533	The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. 2009 , 9, 111		33
1532	Antiviral activity and host gene induction by tamarin and marmoset interferon-alpha and interferon-gamma in the GBV-B primary hepatocyte culture model. <i>Virology</i> , 2009 , 390, 186-96	3.6	6
1531	Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?. 2009 , 81, 198-208		12
1530	Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. 2009 , 83, 135-42		21
1529	A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. 2009 , 83, 148-55		47
1528	Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. 2009 , 49, 12-21		87
1527	Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. 2009 , 49, 364-77		296
1526	HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. 2009 , 49, 745-52		118
1525	Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. 2009 , 49, 1098-112		309
1524	The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. 2009 , 49, 1798-809		66
1523	PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. 2009 , 50, 17-24		117
1522	Hepatitis C virus replication in patients with occult hepatitis C virus infection. 2009 , 49, 2128-9; author reply 2129		4
1521	Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. 2009 , 50, 46-55		105
1520	Reply:. 2009 , 49, 2129-2129		
1519	Experimental models for hepatitis C viral infection. 2009 , 50, 1646-55		64

1518	Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. 2010 , 51, 741-51	52
1517	The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product. 2009 , 61, 739-52	39
1516	293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection. 2009 , 81, 1560-8	10
1515	Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody. 2009 , 81, 1726-33	9
1514	Characterization of the cellular immune response in hepatitis C virus infection. 2009 , 29, 843-66	14
1513	Construction of the Vero cell culture system that can produce infectious HCV particles. 2009 , 36, 111-20	10
1512	[Contribution of molecular biology in the identification of new viruses]. 2009 , 2009, 29-37	
1511	Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. 2009 , 16, 89	36
1510	Hepatitis C virus replicons: dinosaurs still in business?. 2009 , 16, 1-9	11
1509	Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles. 2009 , 16, 621-32	26
1508	Sequential processing of hepatitis C virus core protein by host cell signal peptidase and signal peptide peptidase: a reassessment. 2009 , 16, 705-15	41
1507	Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. 2009 , 6, 235-44	60
1506	The hepatitis C virus enigma. 2009 , 117, 427-39	10
1505	Chronic viral hepatitis is a significant contributor to the immunosenescent phenotype of parenteral drug addiction. 2009 , 14, 214-26	8
1504	New developments in the antiviral treatment of hepatitis C. 2009 , 97, 1-12	10
1503	Protease and polymerase inhibitors for the treatment of hepatitis C. 2009 , 29 Suppl 1, 57-67	61
1502	Primary cultures of human hepatocytes isolated from hepatitis C virus-infected cirrhotic livers as a model to study hepatitis C infection. 2009 , 29, 942-9	5
1501	Antiviral effect of ribonuclease conjugated oligodeoxynucleotides targeting the IRES RNA of the hepatitis C virus. 2009 , 19, 3581-5	6

1500	Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. 2009 , 4, 293-314	17
1499	Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. 2009 , 6, 513-22	182
1498	Lipid droplets and hepatitis C virus infection. 2009 , 1791, 552-9	71
1497	PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control. 2009 , 142, 51-6	35
1496	Cell culture-adaptive mutations in the NS5B gene of hepatitis C virus with delayed replication and reduced cytotoxicity. 2009 , 144, 107-16	11
1495	Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. 2009 , 145, 63-73	72
1494	Efficient replication systems for hepatitis C virus using a new human hepatoma cell line. 2009 , 146, 41-50	39
1493	HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. 2009 , 50, 883-94	59
1492	Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. 2009 , 51, 29-38	53
1491	Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. 2009 , 51, 446-57	62
1490	New insights into hepatitis B and C virus co-infection. 2009 , 51, 423-5	12
1489	Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. 2009 , 29, 171-8	14
1488	New and experimental therapies for HCV. 2009 , 6, 403-11	53
1487	Hepatitis C Virus Genome Replication. 2009 , 61-88	2
1486	Studying HCV RNA synthesis in vitro with replication complexes. 2009 , 510, 177-84	5
1485	Reverse transcription PCR-based sequence analysis of hepatitis C virus replicon RNA. 2009 , 510, 165-75	2
1484	HCV genetic variability: from quasispecies evolution to genotype classification. 2009 , 4, 359-73	39
1483	Mechanisms of HCV survival in the host. 2009 , 6, 217-27	40

1482	Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. 2009 , 137, 673-81	72
1481	The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. 2009 , 137, 1827-35	73
1480	Hepatitis C Virus entry: the early steps in the viral replication cycle. 2009 , 6, 117	26
1479	Lamiridosins, hepatitis C virus entry inhibitors from <i>Lamium album</i> . 2009 , 72, 2158-62	51
1478	Hepatitis C. 2009 ,	2
1477	Hepatitis C virus virology and new treatment targets. 2009 , 7, 329-50	9
1476	Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. 2009 , 4, 399-415	75
1475	Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. 2009 , 6, 103	102
1474	Synthesis of 2'-N-formamido nucleosides and biological evaluation. 2009 , 28, 1042-50	
1473	Determination of total bile acid levels using a thick-film screen-printed Ir/C sensor for the detection of liver disease. 2009 , 134, 973-9	19
1472	Molecular and Contextual Markers of Hepatitis C Virus and Drug Abuse. 2009 , 13, 153-179	2
1471	In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. 2009 , 53, 1377-85	169
1470	Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. 2009 , 457, 882-6	738
1469	Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis. 2009 , 39, 1178-89	9
1468	Caspase inhibitors for the treatment of hepatitis C. 2009 , 13, 467-75	21
1467	Blood-Borne Hepatitis Viruses: Hepatitis Viruses B, C, and D and Candidate Agents of Cryptogenetic Hepatitis. 2009 , 325-362	
1466	The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. 2009 , 423, 303-14	35
1465	Cellular and molecular biology of HCV infection and hepatitis. 2009 , 117, 49-65	98

1464	Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. 2009 , 113, 585-93	64
1463	Occludin, the final essential factor for HCV entry?. 2009 , 4, 329-333	
1462	Molecular Biology of Hepatitis Viruses. 807-834	
1461	HCV NS2/3 protease: a future antiviral drug target?. 2009 , 4, 463-472	1
1460	New perspectives in HCV therapy: entry inhibitors. 2010 , 5, 181-94	2
1459	The Involvement of Tight Junction Protein Claudin-1 in Hepatitis C Virus Entry. 2010 , 65, 273-292	1
1458	Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities. 2010 , 20, 259-68	33
1457	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. <i>Antiviral Therapy</i> , 2010 , 15, 765-786	4
1456	Synthesis and antiviral activity of an imidazo[1,2-a]pyrrolo[2,3-c]pyridine series against the bovine viral diarrhea virus. 2010 , 45, 2044-7	46
1455	Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV). 2010 , 18, 2304-2316	35
1454	Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase. 2010 , 18, 6055-68	29
1453	Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. 2010 , 155, 1735-53	23
1452	Mechanisms of viral entry: sneaking in the front door. 2010 , 244, 15-24	39
1451	Hepatitis C virus experimental model systems and antiviral drug research. 2010 , 25, 227-45	12
1450	Development of novel antiviral therapies for hepatitis C virus. 2010 , 25, 246-66	22
1449	New antiviral therapies for chronic hepatitis C. 2010 , 4, 548-61	89
1448	Update on Specifically Targeted Antiviral Therapy for Hepatitis C Infection: Progress and Pitfalls on the Road to Viral Eradication. 2010 , 9, 125-132	1
1447	Role of lipid metabolism in hepatitis C virus assembly and entry. 2009 , 102, 63-74	84

1446	Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication. 2010 , 169, 380-4		8
1445	Development of novel therapies for hepatitis C. 2010 , 86, 79-92		66
1444	A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. 2010 , 86, 172-9		19
1443	Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection. 2010 , 86, 220-3		9
1442	A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. 2010 , 87, 1-8		41
1441	Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. <i>Virology</i> , 2010 , 398, 57-67	3.6	106
1440	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants. <i>Virology</i> , 2010 , 405, 361-9	3.6	17
1439	The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. <i>Virology</i> , 2010 , 407, 110-9	3.6	14
1438	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. <i>Virology</i> , 2010 , 407, 80-90	3.6	21
1437	Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. 2010 , 51, 43-53		168
1436	MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. 2010 , 51, 1494-504		156
1435	Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis. 2010 , 51, 1922-32		32
1434	Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. 2010 , 52, 443-53		79
1433	Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. 2010 , 52, 845-53		46
1432	Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?. 2010 , 52, 1897-905		72
1431	The entire core protein of HCV JFH1 is required for efficient formation of infectious JFH1 pseudoparticles. 2010 , 82, 783-90		7
1430	A peptide mimotope of hepatitis C virus E2 protein is immunogenic in mice and block human anti-HCV sera. 2010 , 82, 1655-65		8
1429	The cell biology of hepatitis C virus. 2010 , 12, 263-71		34

1428	Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. 2010 , 20, 117-29	96
1427	Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment. 2010 , 30, 311-8	4
1426	Establishment of an indicator cell system for hepatitis C virus. 2010 , 54, 206-20	8
1425	17Estradiol inhibits the production of infectious particles of hepatitis C virus. 2010 , 54, 684-90	50
1424	Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. 2010 , 32, 14-28	93
1423	HCV drug discovery aimed at viral eradication. 2010 , 17, 77-90	61
1422	Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. 2010 , 90, 1727-36	169
1421	Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. 2010 , 90, 1690-703	88
1420	Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. 2010 , 28, 167-71	201
1419	Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 2010 , 16, 1295-8	250
1418	A look behind closed doors: interaction of persistent viruses with dendritic cells. 2010 , 8, 350-60	51
1417	An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model. 2010 , 38, 387-418	10
1416	An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. 2010 , 38, 471-94	6
1415	An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice. 2010 , 5, e9987	8
1414	Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. 2010 , 5, e12856	59
1413	Potential treatment options and future research to increase hepatitis C virus treatment response rate. 2010 , 2010, 125-145	13
1412	Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. 2010 , 202, 984-90	119
1411	Role of annexin A2 in the production of infectious hepatitis C virus particles. 2010 , 84, 5775-89	101

1410	The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. 2010 , 84, 11532-41	108
1409	Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. 2010 , 84, 10999-1009	166
1408	Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. 2010 , 201, 1381-9	61
1407	Evaluation of compound activity against hepatitis C virus in replicon systems. 2010 , Chapter 13, Unit 13B.1	1
1406	Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. 2010 , 91, 681-690	93
1405	Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. 2010 , 84, 10159-68	163
1404	Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. 2010 , 84, 5277-93	109
1403	Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. 2010 , 84, 5494-507	56
1402	The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. 2010 , 59, 1111-9	77
1401	Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. 2010 , 84, 12515-28	31
1400	Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. 2010 , 84, 5067-77	62
1399	Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. 2010 , 84, 4597-610	34
1398	Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins. 2010 , 285, 25802-11	13
1397	The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. 2010 , 202, 65-74	48
1396	Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads. 2010 , 91, 1919-1930	25
1395	Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. 2010 , 207, 2019-31	118
1394	Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. 2010 , 84, 773-87	111
1393	Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. 2010 , 91, 2238-48	28

1392	Species-specific regions of occludin required by hepatitis C virus for cell entry. 2010 , 84, 11696-708	45
1391	Identification of a dominant negative inhibitor of human zinc finger antiviral protein reveals a functional endogenous pool and critical homotypic interactions. 2010 , 84, 4504-12	23
1390	Natural killer cells and hepatitis C virus infection. 2010 , 571-587	
1389	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. 2010 , 54, 1878-87	203
1388	Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. 2010 , 84, 5751-63	174
1387	Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. 2010 , 54, 3355-64	7
1386	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. 2010 , 4, 63-79	7
1385	Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. 2010 , 107, 3141-5	176
1384	A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. 2010 , 107, 3764-9	61
1383	Generation and quantitation of infectious hepatitis C virus derived from cell culture (HCVcc). 2010 , Chapter 13, Unit 13B.4	1
1382	Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. 2010 , 84, 964-75	46
1381	How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. 2010 , 201, 1859-66	63
1380	Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. 2010 , 107, 291-6	96
1379	Detection of Adenosine Deaminase Activity with a Thick-Film Screen-Printed Ir/C Sensor to Detect Liver Disease. 2010 , 157, J130	1
1378	Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. 2010 , 30, 427-31	50
1377	Claudin association with CD81 defines hepatitis C virus entry. 2010 , 285, 21092-102	166
1376	A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. 2010 , 54, 197-206	21
1375	Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. 2010 , 84, 34-43	121

1374	Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription. 2010 , 84, 5824-35		37
1373	Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. 2010 , 91, 2230-7		119
1372	Hepatitis C virus: assembly and release of virus particles. 2010 , 285, 22733-9		84
1371	Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles. 2010 , 91, 362-72		81
1370	Oncogenic potential of hepatitis C virus proteins. 2010 , 2, 2108-33		85
1369	Targeting HCV entry for development of therapeutics. 2010 , 2, 1718-33		23
1368	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. 2010 , 2, 2696-739		31
1367	Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture. <i>PLoS Pathogens</i> , 2010 , 6, e1000910	7.6	13
1366	A new insight into hepatitis C vaccine development. 2010 , 2010, 548280		32
1365	RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells. <i>PLoS Pathogens</i> , 2010 , 6, e1000885	7.6	45
1364	Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. <i>PLoS Pathogens</i> , 2010 , 6, e1001184	7.6	90
1363	Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. <i>PLoS Pathogens</i> , 2010 , 6, e1001233	7.6	144
1362	Lipid metabolism and HCV infection. 2010 , 2, 1195-217		34
1361	Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. <i>PLoS Pathogens</i> , 2010 , 6, e1000764	7.6	200
1360	Hepatitis C virus genomic RNA dimerization is mediated via a kissing complex intermediate. 2010 , 16, 913-25		47
1359	A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. <i>PLoS Pathogens</i> , 2010 , 6, e1001118	7.6	81
1358	The SR-BI partner PDZK1 facilitates hepatitis C virus entry. <i>PLoS Pathogens</i> , 2010 , 6, e1001130	7.6	43
1357	Recent advances in hepatitis C virus cell entry. 2010 , 2, 692-709		21

1356	Last stop before exit - hepatitis C assembly and release as antiviral drug targets. 2010 , 2, 1782-803		4
1355	Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. <i>PLoS Pathogens</i> , 2010 , 6, e1000719	7.6	302
1354	Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. <i>PLoS Pathogens</i> , 2010 , 6, e1000978	7.6	86
1353	Core as a novel viral target for hepatitis C drugs. 2010 , 2, 1734-51		26
1352	Anti-bovine viral diarrhoea virus activity of novel diphenylmethane derivatives. 2010 , 20, 193-200		5
1351	Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. 2010 , 30, 319-32		29
1350	Adaptive immunity to the hepatitis C virus. 2010 , 78, 43-86		53
1349	Genetic analysis of the carboxy-terminal region of the hepatitis C virus core protein. 2010 , 84, 1666-73		34
1348	Cell culture systems for the hepatitis C virus and their application for development of specifically targeted antiviral therapy for hepatitis C (Stat-C). 2010 , 60, 695-696		
1347	New insights into structure and replication of the hepatitis C virus and clinical implications. 2010 , 30, 333-47		61
1346	Lebertoxizität und regulatorische Anforderungen. 2010 , 60, 696-697		
1345	Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. 2010 , 2, 2078-95		37
1344	Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. 2010 , Chapter 17, Unit 17.5.		13
1343	ER targeting and retention of the HCV NS4B protein relies on the concerted action of multiple structural features including its transmembrane domains. 2010 , 27, 45-62		12
1342	Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. 2010 , 7, 318		18
1341	Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. 2010 , 7, 36		23
1340	Thermal stability and inactivation of hepatitis C virus grown in cell culture. 2010 , 7, 40		67
1339	Increased susceptibility of Huh7 cells to HCV replication does not require mutations in RIG-I. 2010 , 7, 44		15

1338	Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. 2010 , 138, 1909-19	24
1337	Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. 2010 , 138, 1134-42	62
1336	Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. 2010 , 138, 1112-22	123
1335	Hepatitis C virus infection of neuroepithelioma cell lines. 2010 , 139, 1365-74	51
1334	Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. 2010 , 139, 1355-64	126
1333	Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. 2010 , 139, 1774-83, 1783.e1-6	52
1332	New cell culture models of hepatitis C virus entry, replication, and virus production. 2010 , 139, 1090-3	2
1331	ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. 2010 , 91, 382-8	85
1330	Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. 2010 , 84, 647-60	121
1329	Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. 2010 , 84, 11905-15	165
1328	General review on in vitro hepatocyte models and their applications. 2010 , 640, 1-40	172
1327	Advances and challenges in studying hepatitis C virus in its native environment. 2010 , 4, 541-50	19
1326	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. 2010 , 16, 277-86	56
1325	Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. 2010 , 52, 183-90	62
1324	Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes. 2010 , 112, 107-16	22
1323	Structural characterization of the transmembrane proximal region of the hepatitis C virus E1 glycoprotein. 2010 , 1798, 344-53	29
1322	Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. 2010 , 395, 565-71	9
1321	Hepatitis C virus hijacks host lipid metabolism. 2010 , 21, 33-40	251

1320	Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. 2010 , 28, 4138-44	17
1319	Natural killer cells in viral hepatitis: facts and controversies. 2010 , 40, 851-63	67
1318	Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. 2010 , 49, 1822-32	28
1317	Hepatocytes. 2010 ,	5
1316	Genomics and the Management of Hepatitis. 2010 , 774-785	
1315	Recent Advances in Hepatitis C Therapies. 2010 , 169-218	
1314	A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization. 2010 , 8, 96-105	20
1313	Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. 2010 , 84, 9170-80	60
1312	Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. 2011 , 286, 30361-30376	75
1311	Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. 2011 , 85, 8556-68	73
1310	Mouse hepatic cells support assembly of infectious hepatitis C virus particles. 2011 , 141, 1057-66	93
1309	Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. 2011 , 140, 676-685.e1	46
1308	Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon- β . 2011 , 140, 1032-42	120
1307	Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. 2011 , 1, 19-26	25
1306	A genetically humanized mouse model for hepatitis C virus infection. 2011 , 474, 208-11	298
1305	HCV Viral Entry Inhibitors. 2011 , 329-337	
1304	Selection of hepatitis C virus resistant to ribavirin. 2011 , 8, 402	24
1303	Characterization of a canine homolog of hepatitis C virus. 2011 , 108, 11608-13	208

1302	Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. 2011 , 141, 1067-79	124
1301	Telaprevir user's guide. 2011 , 15, 555-71	14
1300	Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. 2011 , 203, 1753-62	121
1299	Turning hepatitis C into a real virus. 2011 , 65, 307-27	50
1298	MicroRNAs as post-transcriptional machines and their interplay with cellular networks. 2011 , 722, 59-74	73
1297	Mixing the right hepatitis C inhibitor cocktail. 2011 , 17, 34-46	31
1296	Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. 2011 , 54, 566-76	143
1295	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. 2011 , 55, 11-8	9
1294	Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. 2011 , 13, e13	32
1293	Production and characterization of HCV particles from serum-free culture. 2011 , 29, 4821-8	15
1292	New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. 2011 , 30, 69-77	25
1291	A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. 2011 , 155, 406-14	23
1290	Cholesterol and chronic hepatitis C virus infection. 2011 , 41, 697-710	14
1289	HBV & HCV Immunopathogenesis. 2011 ,	
1288	Toll Like Receptors in Chronic Viral Hepatitis IFriend and Foe. 2011 ,	
1287	. 2011 ,	6
1286	. 2011 ,	9
1285	Boceprevir in the treatment of chronic hepatitis C virus infection. 2011 , 7	

1284	RNA interference as therapeutics for hepatocellular carcinoma. 2011 , 6, 106-15	27
1283	Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain. 2011 , 6, e15916	7
1282	Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. 2011 , 6, e18933	23
1281	Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. 2011 , 6, e21186	27
1280	Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. 2011 , 6, e23587	11
1279	Metabolomic profile of hepatitis C virus-infected hepatocytes. 2011 , 6, e23641	66
1278	HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. 2011 , 6, e24660	84
1277	Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. 2011 , 6, e25789	5
1276	Core-Lations Between Intrinsic Disorder and Multifaceted Activities in Hepatitis C Virus and Related Viruses. 2011 , 375-407	
1275	NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. 2011 , 85, 6963-76	96
1274	HCV replication and assembly: a play in one act. 2011 , 6, 985-995	3
1273	Culturing HCV: challenges and progress. 2011 , 6, 1169-1178	1
1272	.	2
1271	Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. <i>Antiviral Therapy</i> , 2011 , 16, 705-18	1.6 20
1270	Fluoroquinolones inhibit HCV by targeting its helicase. <i>Antiviral Therapy</i> , 2012 , 17, 467-76	1.6 20
1269	Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. 2011 , 13, 24-32	14
1268	Assembly of hepatitis C virus particles. 2011 , 55, 12-8	9
1267	Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. 2011 , 55, 774-82	30

1266	Comparison of envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. 2011 , 18, 181-92			2
1265	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. 2011 , 18, 562-70			19
1264	Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes. 2011 , 18, e568-77			17
1263	Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C. 2011 , 31, 871-80			5
1262	2,3-Dihydro-1,2-Diphenyl-substituted 4H-Pyridinone derivatives as new anti Flaviviridae inhibitors. 2011 , 77, 441-9			9
1261	Cell defense systems against oxidative stress and endoplasmic reticulum stress: Mechanisms of regulation and the effect of hepatitis C virus. 2011 , 45, 110-122			9
1260	A diverse range of gene products are effectors of the type I interferon antiviral response. 2011 , 472, 481-5			1584
1259	Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid. 2011 , 171, 169-75			2
1258	Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography. <i>Virology</i> , 2011 , 409, 148-55	3.6		22
1257	Hepatitis C virus-induced furin and thrombospondin-1 activate TGF- β : role of TGF- β in HCV replication. <i>Virology</i> , 2011 , 412, 284-96	3.6		54
1256	The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. <i>Virology</i> , 2011 , 414, 10-8	3.6		69
1255	Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. <i>Virology</i> , 2011 , 421, 222-34	3.6		19
1254	An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones. 2011 , 12, 485			19
1253	Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. 2011 , 8, 112			11
1252	Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. 2011 , 89, 54-63			33
1251	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. 2011 , 89, 136-48			39
1250	Human immunodeficiency virus-1 Rev protein activates hepatitis C virus gene expression by directly targeting the HCV 5'-untranslated region. 2011 , 585, 4002-9			7
1249	Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. 2011 , 21, 6852-5			19

1248	Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. 2011 , 18, 1453-62	40
1247	Current perspective of HCV NS5B inhibitors: a review. 2011 , 18, 5564-97	27
1246	Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. 2011 , 21, 1811-30	22
1245	Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN- γ secretion activity. 2011 , 46, 232-41	29
1244	Establishment of infectious HCV virion-producing cells with newly designed full-genome replicon RNA. 2011 , 156, 295-304	2
1243	Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. 2011 , 156, 433-42	19
1242	Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase. 2011 , 68, 505-22	13
1241	Molekulare Diagnostik und zukünftige Therapien bei Hepatitis C. 2011 , 6, 98-105	
1240	Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. 2011 , 10, 214-227	46
1239	HCV entry receptors as potential targets for siRNA-based inhibition of HCV. 2011 , 9, 15	13
1238	In-vitro model systems to study Hepatitis C Virus. 2011 , 9, 7	16
1237	Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs. 2011 , 8, 221	9
1236	Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. 2011 , 83, 1005-15	18
1235	In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. 2011 , 53, 755-62	99
1234	Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). 2011 , 53, 1090-9	63
1233	Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. 2011 , 53, 1846-53	14
1232	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. 2011 , 54, 425-33	17
1231	Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. 2011 , 54, 1901-12	74

1230	Hepatitis C virus induces interferon- γ and interferon-stimulated genes in primary liver cultures. 2011 , 54, 1913-23	143
1229	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. 2011 , 54, 1947-55	207
1228	Synthesis and biological evaluation of β -ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. 2011 , 19, 4067-74	96
1227	Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. 2011 , 6, 279-94	14
1226	A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus. 2011 , 85, 12351-61	36
1225	Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. 2011 , 85, 596-605	186
1224	MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. 2011 , 108, 4991-6	154
1223	Hepatitis C virus and host cell lipids: an intimate connection. 2011 , 8, 258-69	128
1222	Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production. 2011 , 85, 11022-37	31
1221	Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III. 2011 , 85, 6645-56	36
1220	Charged residues in hepatitis C virus NS4B are critical for multiple NS4B functions in RNA replication. 2011 , 85, 8158-71	19
1219	Production of hepatitis C virus lacking the envelope-encoding genes for single-cycle infection by providing homologous envelope proteins or vesicular stomatitis virus glycoproteins in trans. 2011 , 85, 2138-47	17
1218	Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. 2011 , 85, 12557-69	50
1217	Efficient production of antibodies against a mammalian integral membrane protein by phage display. 2011 , 24, 679-89	36
1216	Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase. 2011 , 92, 101-11	28
1215	Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. 2011 , 85, 1706-17	109
1214	Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. 2011 , 204, 609-16	11
1213	Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. 2011 , 85, 4246-57	46

1212	Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection. 2011 , 85, 5513-23	14
1211	The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. 2011 , 92, 112-21	40
1210	Inefficient fusion due to a lack of attachment receptor/co-receptor restricts productive human immunodeficiency virus type 1 infection in human hepatoma Huh7.5 cells. 2011 , 92, 587-97	6
1209	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus. 2011 , 85, 13185-94	65
1208	A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. 2011 , 3, 94ra71	107
1207	Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. 2011 , 85, 2224-34	115
1206	HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. 2011 , 85, 12087-92	107
1205	Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. 2011 , 85, 2793-802	63
1204	Griffithsin has antiviral activity against hepatitis C virus. 2011 , 55, 5159-67	112
1203	Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. 2011 , 85, 2891-906	61
1202	Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. 2011 , 85, 7989-8001	75
1201	Expression of E1E2 on hepatitis C RNA-containing particles released from primary cultured human hepatocytes derived from infected cirrhotic livers. 2011 , 54, 1-9	3
1200	Bile acids promote HCV replication through the EGFR/ERK pathway in replicon-harboring cells. 2011 , 54, 339-48	12
1199	Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. 2011 , 55, 2197-205	19
1198	Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection. 2011 , 55, 2537-45	11
1197	Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. 2011 , 85, 8913-28	73
1196	Conserved GXXXG- and S/T-like motifs in the transmembrane domains of NS4B protein are required for hepatitis C virus replication. 2011 , 85, 6464-79	24
1195	TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. 2011 , 85, 3733-45	68

1194	Directly acting antivirals against hepatitis C virus. 2011 , 66, 1673-86	75
1193	Scavenger receptor class B, type I: a promising immunotherapy target. 2011 , 3, 395-406	14
1192	Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. 2011 , 108, 10290-5	29
1191	The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly. 2011 , 85, 1193-204	38
1190	Infections and the liver. 2011 , 29, 184-90	2
1189	Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. 2011 , 286, 31984-92	36
1188	Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. 2011 , 286, 3018-32	273
1187	Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP). 2011 , 286, 26603-15	14
1186	Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry. 2011 , 286, 23865-76	25
1185	Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. 2011 , 85, 1777-92	62
1184	Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. 2011 , 85, 86-97	121
1183	Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. 2011 , 286, 11265-74	70
1182	Hepatitis C virus co-opts Ras-GTPase-activating protein-binding protein 1 for its genome replication. 2011 , 85, 6996-7004	52
1181	Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics. 2011 , 85, 3978-85	30
1180	Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. 2011 , 286, 44218-44233	26
1179	The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. 2011 , 92, 233-46	200
1178	Simplified RNA secondary structure mapping by automation of SHAPE data analysis. 2011 , 39, e151	34
1177	Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. 2011 , 85, 7005-19	102

1176	Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. 2011 , 85, 946-56		39
1175	Animal models in the study of hepatitis C virus-associated liver pathologies. 2011 , 5, 341-52		21
1174	Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. 2011 , 7, e1002307		18
1173	Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. <i>PLoS Pathogens</i> , 2011 , 7, e1002029	7.6	22
1172	Hepatitis C virus entry and the tetraspanin CD81. 2011 , 39, 532-6		37
1171	Inactivation and survival of hepatitis C virus on inanimate surfaces. 2011 , 204, 1830-8		80
1170	A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly. <i>PLoS Pathogens</i> , 2011 , 7, e1002144	7.6	120
1169	Hepatitis C virus assembly imaging. 2011 , 3, 2238-54		17
1168	A new model to produce infectious hepatitis C virus without the replication requirement. <i>PLoS Pathogens</i> , 2011 , 7, e1001333	7.6	13
1167	The hepatitis C virus glycan shield and evasion of the humoral immune response. 2011 , 3, 1909-32		74
1166	Trafficking of hepatitis C virus core protein during virus particle assembly. <i>PLoS Pathogens</i> , 2011 , 7, e1002302		97
1165	NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. <i>PLoS Pathogens</i> , 2011 , 7, e1001278	7.6	126
1164	Role of Toll-like receptors in liver health and disease. 2011 , 121, 415-26		66
1163	Interferon β -stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. 2012 , 205, 1351-62		37
1162	Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. <i>PLoS Pathogens</i> , 2012 , 8, e1002895	7.6	118
1161	Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. 2012 , 287, 5042-58		37
1160	Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. 2012 , 2012, 807351		16
1159	Molecular determinants and dynamics of hepatitis C virus secretion. <i>PLoS Pathogens</i> , 2012 , 8, e1002466	7.6	137

1158	Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. <i>PLoS Pathogens</i> , 2012 , 8, e1002696	7.6	32
1157	Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. 2012 , 443, 85-94		37
1156	Compounds from <i>Arnebia euchroma</i> and their related anti-HCV and antibacterial activities. 2012 , 78, 39-45		34
1155	Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. <i>PLoS Pathogens</i> , 2012 , 8, e1002617	7.6	135
1154	Hepatitis C virus and natural compounds: a new antiviral approach?. 2012 , 4, 2197-217		94
1153	Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. 2012 , 2012, 709853		6
1152	Advancement in the development of models for hepatitis C research. 2012 , 2012, 346761		8
1151	Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. <i>PLoS Pathogens</i> , 2012 , 8, e1003056	7.6	361
1150	Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis. 2012 , 86, 5080-8		30
1149	Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. 2012 , 86, 11919-25		77
1148	Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. 2012 , 56, 5365-73		104
1147	Hepatitis C virus infection alters P-body composition but is independent of P-body granules. 2012 , 86, 8740-9		27
1146	Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1B. 2012 , 86, 12903-11		25
1145	Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. 2012 , 287, 35631-35645		41
1144	Role for TBC1D20 and Rab1 in hepatitis C virus replication via interaction with lipid droplet-bound nonstructural protein 5A. 2012 , 86, 6491-502		40
1143	Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. 2012 , 287, 31242-57		87
1142	Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. 2012 , 86, 7107-17		26
1141	Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone. 2012 , 86, 10805-20		37

1140	HCV infection by cell-to-cell transmission: choice or necessity?. 2012 , 12, 83-95		16
1139	Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. 2012 , 86, 10935-49		99
1138	Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. <i>PLoS Pathogens</i> , 2012 , 8, e1002845	7.6	106
1137	Emerging role of lipid droplets in host/pathogen interactions. 2012 , 287, 2280-7		72
1136	Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. 2012 , 86, 1544-54		55
1135	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. 2012 , 109, 19757-62		95
1134	Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. 2012 , 56, 6109-20		8
1133	Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity. 2012 , 86, 679-90		16
1132	Modeling hepatitis C virus infection using human induced pluripotent stem cells. 2012 , 109, 2544-8		175
1131	Structural analysis of hepatitis C virus core-E1 signal peptide and requirements for cleavage of the genotype 3a signal sequence by signal peptide peptidase. 2012 , 86, 7818-28		18
1130	Serology-enabled discovery of genetically diverse hepaciviruses in a new host. 2012 , 86, 6171-8		183
1129	Development of hepatitis C virus production reporter-assay systems using two different hepatoma cell lines. 2012 , 93, 1422-1431		8
1128	In vitro systems for the study of hepatitis C virus infection. 2012 , 2012, 292591		18
1127	Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. 2012 , 86, 2739-49		48
1126	Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly. 2012 , 86, 13025-37		37
1125	Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. 2012 , 205, 656-62		56
1124	Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. 2012 , 109, 6205-10		256
1123	Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. 2012 , 86, 2143-52		12

1122	Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. 2012 , 86, 1382-93	76
1121	Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33. 2012 , 93, 83-92	89
1120	Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. 2012 , 205, 763-71	122
1119	A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication. 2012 , 40, 6908-21	57
1118	Hepatitis C and Hepatocellular Carcinoma: Implications for Pathogenesis and Treatment. 2012 , 143-203	
1117	Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. 2012 , 86, 12616-24	30
1116	Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. 2012 , 86, 11043-56	89
1115	Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. 2012 , 12, 558-70	345
1114	New hepatitis C virus drug discovery strategies and model systems. 2012 , 7, 849-59	2
1113	Direct-acting and host-targeting HCV inhibitors: current and future directions. 2012 , 2, 588-98	29
1112	Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV). 2012 , 55, 7650-66	40
1111	Hepatitis C virus infects the endothelial cells of the blood-brain barrier. 2012 , 142, 634-643.e6	161
1110	Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. 2012 , 55, 2481-531	219
1109	Molecular pathways for glucose homeostasis, insulin signaling and autophagy in hepatitis C virus induced insulin resistance in a cellular model. <i>Virology</i> , 2012 , 434, 5-17	3.6 12
1108	The specific infectivity of hepatitis C virus changes through its life cycle. <i>Virology</i> , 2012 , 433, 462-70	3.6 26
1107	PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. 2012 , 56, 672-81	27
1106	Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. 2012 , 109, E1101-10	70
1105	Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. 2012 , 134, 6896-9	34

1104	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. <i>Virology</i> , 2012 , 432, 29-38	3.6	23
1103	An alternative -1/+2 open reading frame exists within viral N(pro)(1-19) region of bovine viral diarrhea virus SD-1. 2012 , 163, 341-51		4
1102	Multiple effects of Honokiol on the life cycle of hepatitis C virus. 2012 , 32, 989-97		46
1101	Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. 2012 , 86, 11558-66		33
1100	Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. 2012 , 86, 7256-67		128
1099	A dual role for hypoxia inducible factor-1 α in the hepatitis C virus lifecycle and hepatoma migration. 2012 , 56, 803-9		65
1098	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. 2012 , 57, 17-23		64
1097	The metabolic regulator PGC-1 α links hepatitis C virus infection to hepatic insulin resistance. 2012 , 57, 867-73		27
1096	Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production. 2012 , 14, 69-78		4
1095	Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. 2012 , 22, 4955-61		19
1094	[Current indications for triple therapy in hepatitis C virus infection]. 2012 , 35, 266-77		
1093	Two methods of heterokaryon formation to discover HCV restriction factors. 2012 , e4029		
1092	Hepatitis C virus NS3/4A protease blocks IL-28 production. 2012 , 42, 2374-82		32
1091	Topological analysis of protein co-abundance networks identifies novel host targets important for HCV infection and pathogenesis. 2012 , 6, 28		47
1090	Distinct and overlapping genomic profiles and antiviral effects of Interferon- α and - β on HCV-infected and noninfected hepatoma cells. 2012 , 19, 843-53		38
1089	The conserved lysine 151 of HCV NS5B modulates viral genome replication and infectious virus production. 2012 , 19, 862-6		2
1088	Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. 2012 , 48, 313-21		47
1087	HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. 2012 , 142, 978-88		218

1086	Animal models for the study of hepatitis C virus infection and related liver disease. 2012 , 142, 1279-1287.e3	99
1085	Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. 2012 , 143, 429-38.e8	38
1084	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. 2012 , 96, 82-9	23
1083	Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. 2012 , 96, 245-55	15
1082	Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin. 2012 , 96, 260-8	12
1081	Reverse Genetic Tools to Study Hepatitis C Virus. 2012 , 64-90	
1080	Hepatitis C Therapy: Lessons of the Last Two Decades. 2012 , 11, 119-127	1
1079	Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway. 2012 , 27, 278-85	19
1078	Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. 2012 , 7, 597-611	31
1077	Bioportide: an emergent concept of bioactive cell-penetrating peptides. 2012 , 69, 2951-66	30
1076	Low-level HIV infection of hepatocytes. 2012 , 9, 157	33
1075	Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. 2012 , 7, e32207	18
1074	Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions. 2012 , 7, e43960	15
1073	The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. 2012 , 7, e47904	17
1072	Endogenous hepatitis C virus homolog fragments in European rabbit and hare genomes replicate in cell culture. 2012 , 7, e49820	3
1071	Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. 2012 , 7, e52651	16
1070	A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest. 2012 , 7, e52697	11
1069	A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. 2012 , 7, e53254	6

1068	Tissue-Based Model of HCV Replication as a Replacement for Animal Models in Drug Testing. 2012,	
1067	Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. 2011, 2, 278	14
1066	Morphogenesis of infectious hepatitis C virus particles. 2012, 3, 38	18
1065	Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. 2012, 3, 54	26
1064	Hepatitis C virus activates interleukin-1 β via caspase-1-inflammasome complex. 2012, 93, 235-246	113
1063	Hepatitis C virus induces CD81 and claudin-1 endocytosis. 2012, 86, 4305-16	99
1062	Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. 2012, 86, 7334-44	41
1061	Occult infection with hepatitis C virus: friend or foe?. 2012, 90, 763-73	11
1060	Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. 2012, 86, 8581-91	64
1059	High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. 2012, 9, 840-6	299
1058	Human immunodeficiency virus enhances hepatitis C virus replication by differential regulation of IFN and TGF family genes. 2012, 84, 1344-52	7
1057	Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. 2012, 56, 484-91	54
1056	Hepatitis C virus infection enhances TNF α -induced cell death via suppression of NF- κ B. 2012, 56, 831-40	60
1055	Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: a relevant ex vivo model of liver infection. 2012, 56, 861-72	32
1054	New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. 2012, 13, 56-82	10
1053	Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. 2012, 55 Suppl 1, S25-32	38
1052	Assays for RNA synthesis and replication by the hepatitis C virus. 2012, 7, 233-245	1
1051	Humanized murine model for HBV and HCV using human induced pluripotent stem cells. 2012, 35, 261-9	15

1050	(-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. 2012 , 157, 1301-12			73
1049	Telaprevir user's guide. 2012 , 32 Suppl 1, 17-25			7
1048	Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C. 2012 , 19, e154-62			8
1047	Modulation of the type I interferon pathways by culture-adaptive hepatitis C virus core mutants. 2012 , 586, 1272-8			12
1046	Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. 2012 , 52, 1135-50			55
1045	Development of a reporter bovine viral diarrhea virus and initial evaluation of its application for high throughput antiviral drug screening. 2012 , 180, 54-61			6
1044	A compartmentalization model of hepatitis C virus replication: an appropriate distribution of HCV RNA for the effective replication. 2012 , 300, 110-7			15
1043	An overview: in vitro models of HCV replication in different cell cultures. 2012 , 12, 13-20			12
1042	The N-terminal helix (H) of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex. <i>Virology</i> , 2012 , 422, 214-23	3.6		13
1041	An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture. <i>Virology</i> , 2012 , 422, 224-34	3.6		11
1040	Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. <i>Virology</i> , 2012 , 425, 31-9	3.6		62
1039	Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. <i>Virology</i> , 2012 , 428, 98-111	3.6		38
1038	In vitro models for analysis of the hepatitis C virus life cycle. 2012 , 56, 1-9			6
1037	Replication and infectivity of a novel genotype 1b hepatitis C virus clone. 2012 , 56, 308-17			19
1036	Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell. 2012 , 9, 11			16
1035	Permissiveness of human hepatoma cell lines for HCV infection. 2012 , 9, 30			13
1034	A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. 2012 , 55, 364-72			101
1033	Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. 2012 , 55, 634-41			45

1032	A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization. 2012 , 84, 229-34	2
1031	Inhibition of hepatitis C virus replication by single and dual small interfering RNA using an HCV-infected cell model. 2012 , 34, 295-301	9
1030	Novel therapies for hepatitis C - one pill fits all?. 2013 , 12, 595-610	156
1029	Characterizations of HCV NS5A replication complex inhibitors. <i>Virology</i> , 2013 , 444, 343-54	3.6 39
1028	Fetal bovine serum inhibits hepatitis C virus attachment to host cells. 2013 , 193, 261-9	6
1027	Entry and replication of recombinant hepatitis C viruses in cell culture. 2013 , 59, 233-48	39
1026	Completion of the entire hepatitis C virus life cycle in genetically humanized mice. 2013 , 501, 237-41	184
1025	Role of miR-122 and lipid metabolism in HCV infection. 2013 , 48, 169-76	28
1024	Different responses of two highly permissive cell lines upon HCV infection. 2013 , 28, 202-8	5
1023	High-throughput screening using dengue virus reporter genomes. 2013 , 1030, 205-19	44
1022	Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection. 2013 , 145, 966-969.e7	36
1021	PML tumor suppressor protein is required for HCV production. 2013 , 430, 592-7	11
1020	Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. 2013 , 145, 1414-23.e1	27
1019	BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. 2013 , 98, 54-60	29
1018	Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. 2013 , 17, 194-204	13
1017	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. 2013 , 58, 1587-97	33
1016	Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. 2013 , 87, 12776-93	20
1015	Identification and comparative analysis of hepatitis C virus-host cell protein interactions. 2013 , 9, 3199-209	41

1014	Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. 2013 , 191, 3308-18	35
1013	Progress towards a hepatitis C virus vaccine. 2013 , 2, e79	35
1012	Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals. 2013 , 99, 6-11	14
1011	Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. 2013 , 20, 478-85	14
1010	Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells. 2013 , 174, 265-73	16
1009	Study of hepatitis C virus entry in genetically humanized mice. 2013 , 59, 249-57	15
1008	Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. 2013 , 10, 259	35
1007	Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. 2013 , 13, 187	116
1006	The ins and outs of hepatitis C virus entry and assembly. 2013 , 11, 688-700	261
1005	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines. 2013 , 69, 32-43	20
1004	The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus. 2013 , 587, 156-64	43
1003	Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7. 2013 , 94, 2221-2235	16
1002	Hepatitis C virus: standard-of-care treatment. 2013 , 67, 169-215	41
1001	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. 2013 , 12, 200-213	4
1000	Serum prolactin levels and prolactin mRNA expression in peripheral blood mononuclear cells in hepatitis C virus infection. 2013 , 85, 1199-205	4
999	Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 2013 , 19, 837-49	425
998	Cytoskeletal proteins: shaping progression of hepatitis C virus-induced liver disease. 2013 , 302, 279-319	2
997	Sequential biogenesis of host cell membrane rearrangements induced by hepatitis C virus infection. 2013 , 70, 1297-306	55

996	Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules. <i>Virology</i> , 2013 , 435, 472-84	3.6	65
995	Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. 2013 , 94, 996-1008		10
994	Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein. 2013 , 87, 1605-17		38
993	A hepatitis C virus NS5A phosphorylation site that regulates RNA replication. 2013 , 87, 1255-60		33
992	Hepatitis C vaccines. 2013 , 1074-1084		
991	Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products. 2013 , 53, 1010-8		42
990	Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. 2013 , 87, 581-96		10
989	Innate immune responses in hepatitis C virus infection. 2013 , 35, 53-72		61
988	Lipids and HCV. 2013 , 35, 87-100		73
987	Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. 2013 , 57, 70-80		39
986	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. 2013 , 57, 46-58		104
985	Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. <i>Virology</i> , 2013 , 439, 23-33	3.6	15
984	Emerging therapeutic targets for hepatitis C virus infection. 2013 , 11, 612-9.e1		10
983	The Arg719 residue at the C-terminal end of the stem region in hepatitis C virus JFH-1 E2 glycoprotein promotes viral infection. 2013 , 172, 1-8		7
982	Stable Huh-7 cell lines expressing non-structural proteins of genotype 1a of hepatitis C virus. 2013 , 189, 65-9		7
981	Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. 2013 , 57, 4937-44		35
980	Structure and Molecular Virology. 2013 , 219-245		
979	Animal Models of Hepatitis C Virus Infection. 2013 , 280-294		

978 In Vitro Replication Models. **2013**, 325-340

977 The p7 protein of hepatitis C virus is degraded via the proteasome-dependent pathway. **2013**, 176, 211-5 10

976 Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. **2013**, 425, 1899-1914 88

975 Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. *Virology*, **2013**, 443, 80-8 3.6 16

974 Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. *Virology*, **2013**, 439, 13-22 3.6 33

973 The DEAD-box RNA helicase DDX5 acts as a positive regulator of Japanese encephalitis virus replication by binding to viral 3' UTR. **2013**, 100, 487-99 42

972 [The molecular biology of hepatitis C virus]. **2013**, 36, 280-93 5

971 Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives. **2013**, 440, 515-20 19

970 Oleanolic acid and ursolic acid: novel hepatitis C virus antivirals that inhibit NS5B activity. **2013**, 98, 44-53 92

969 Hepatitis C virus vaccines in the era of new direct-acting antivirals. **2013**, 7, 171-85 9

968 EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry. **2013**, 15, 1234-52 34

967 Optimal treatment with telaprevir for chronic HCV infection. **2013**, 33 Suppl 1, 3-13 6

966 Cell culture systems for hepatitis C virus. **2013**, 369, 17-48 65

965 Virion assembly and release. **2013**, 369, 199-218 84

964 Innate immune responses to hepatitis C virus. **2013**, 369, 219-42 34

963 Broadly neutralizing antiviral antibodies. **2013**, 31, 705-42 351

962 Antiviral Drug Discovery. **2013**, 439-515

961 Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection. **2013**, 34, 3846-57 29

960	Hepatitis C virus vaccines--progress and perspectives. 2013 , 58, 66-72	31
959	A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. 2013 , 8, e59776	112
958	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. 2013 , 21, 4432-41	62
957	Major models of HCV infection. 2013 , 8, 493-506	3
956	Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. 2013 , 145, 447-55.e1-4	50
955	The unfolded protein response element IRE1 β senses bacterial proteins invading the ER to activate RIG-I and innate immune signaling. 2013 , 13, 558-569	92
954	The Role of CD81 in HCV and Plasmodium Infection. 2013 , 345-386	
953	Telaprevir for chronic hepatitis C virus infection. 2013 , 17, 47-62	2
952	Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. <i>Virology</i> , 2013 , 444, 1-113.6	45
951	Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. 2013 , 5, 1292-324	99
950	Antiviral Methods and Protocols. 2013 ,	3
949	Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. 2013 , 125, 439-48	20
948	Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection. 2013 , 58, 1569-79	21
947	The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. 2013 , 11, 482-96	290
946	Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. 2013 , 145, 658-67.e11	6
945	Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. 2013 , 95, 96-102	26
944	PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. 2013 , 59, 420-6	29
943	Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. 2013 , 87, 37-51	93

942	Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. 2013 , 22, 853-62		1
941	Genome-wide analysis of host mRNA translation during hepatitis C virus infection. 2013 , 87, 6668-77		20
940	Identification of rodent homologs of hepatitis C virus and pegiviruses. 2013 , 4, e00216-13		146
939	Selecting and characterizing drug-resistant hepatitis C virus replicon. 2013 , 1030, 93-103		3
938	Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. 2013 , 87, 7593-607		64
937	Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. 2013 , 57, 1291-303		33
936	Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. <i>PLoS Pathogens</i> , 2013 , 9, e1003228	7.6	36
935	HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. <i>PLoS Pathogens</i> , 2013 , 9, e1003248	7.6	184
934	IL-1 β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. <i>PLoS Pathogens</i> , 2013 , 9, e1003330	7.6	302
933	hepatitis c Virus p7 is critical for capsid assembly and envelopment. <i>PLoS Pathogens</i> , 2013 , 9, e1003355	7.6	92
932	Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. <i>PLoS Pathogens</i> , 2013 , 9, e1003244	7.6	59
931	Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B. 2013 , 87, 7409-22		26
930	Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein. 2013 , 87, 4130-45		17
929	The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. 2013 , 41, 3688-98		11
928	Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. 2013 , 87, 8545-58		15
927	Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. 2013 , 87, 1385-99		21
926	Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. 2013 , 57, 2571-81		37
925	Inactivation of hepatitis C virus infectivity by human breast milk. 2013 , 208, 1943-52		37

924	Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. 2013 , 87, 8282-93	63
923	Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. 2013 , 207, 281-7	50
922	Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. 2013 , 62, 1193-203	37
921	Systematic analysis of enhancer and critical cis-acting RNA elements in the protein-encoding region of the hepatitis C virus genome. 2013 , 87, 5678-96	27
920	Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. 2013 , 87, 5065-80	32
919	A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production. 2013 , 87, 11704-20	37
918	Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment. 2013 , 87, 13297-306	18
917	Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. 2013 , 87, 1664-78	38
916	Efficiency of E2-p7 processing modulates production of infectious hepatitis C virus. 2013 , 87, 11255-66	17
915	Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor. 2013 , 57, 6034-49	16
914	Are trans-complementation systems suitable for hepatitis C virus life cycle studies?. 2013 , 20, 225-33	3
913	Tetraspanins. 2013 ,	10
912	Low oxygen tension enhances hepatitis C virus replication. 2013 , 87, 2935-48	43
911	Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. 2013 , 5, 776-86	10
910	Antiviral agents for analyzing virus life cycle: chemical genetics for virology. 2013 , 133, 1169-75	2
909	Development of a dendritic cell vaccine encoding multiple cytotoxic T lymphocyte epitopes targeting hepatitis C virus. 2013 , 32, 901-9	4
908	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon- γ in response to hepatitis C virus. 2013 , 57, 1705-15	74
907	Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. 2013 , 58, 1907-17	49

906	Evolution of cell culture systems for HCV. <i>Antiviral Therapy</i> , 2013 , 18, 523-30	1.6	10
905	An insight into the diagnosis and pathogenesis of hepatitis C virus infection. 2013 , 19, 7896-909		43
904	Viral Hepatitis. 2013 , 1173-1190		
903	Active RNA replication of hepatitis C virus downregulates CD81 expression. 2013 , 8, e54866		6
902	Systematic functional comparative analysis of four single-stranded DNA-binding proteins and their affection on viral RNA metabolism. 2013 , 8, e55076		14
901	Activation of TGF- β promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF- β in hepatic stellate cell activation and invasion. 2013 , 8, e56367		64
900	Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. 2013 , 8, e62674		8
899	A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. 2013 , 8, e64221		48
898	2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinase. 2013 , 8, e64932		12
897	Hepatitis C virus non-structural protein 3 interacts with cytosolic 5'(3')-deoxyribonucleotidase and partially inhibits its activity. 2013 , 8, e68736		3
896	Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. 2013 , 8, e70809		21
895	Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. 2013 , 8, e71039		52
894	Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs. 2013 , 8, e74027		4
893	Chimeric mouse model for the infection of hepatitis B and C viruses. 2013 , 8, e77298		48
892	GPS2 is required for the association of NS5A with VAP-A and hepatitis C virus replication. 2013 , 8, e78195		6
891	Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain HCV-RMT. 2013 , 8, e82527		3
890	A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication. 2013 , 8, e84022		1
889	Use of proteomic analysis tools to identify HCV-proteins down-regulated by acetylsalicylic acid. 2013 , 12, 725-732		8

888	Pegylated interferon- α b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells. 2013 , 12, 448-457	7
887	Enhanced virus-specific CD8+ T cell responses by <i>Listeria monocytogenes</i> -infected dendritic cells in the context of Tim-3 blockade. 2014 , 9, e87821	9
886	GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion. 2014 , 9, e90553	15
885	Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation. 2014 , 9, e92343	6
884	MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. 2014 , 9, e94501	25
883	Single strain isolation method for cell culture-adapted hepatitis C virus by end-point dilution and infection. 2014 , 9, e98168	7
882	Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. 2014 , 9, e98877	6
881	Nonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport. 2014 , 9, e99022	17
880	The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. 2014 , 9, e99601	5
879	CD100 up-regulation induced by interferon- γ on B cells is related to hepatitis C virus infection. 2014 , 9, e113338	8
878	Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. 2014 , 5, 329	48
877	Recent advances in HCV entry. 2014 , 9, 189-205	2
876	Development of hepatitis C virus genotype 3a cell culture system. 2014 , 60, 1838-50	37
875	Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. 2014 , 6, 676-84	25
874	Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. 2014 , 58, 38-47	25
873	Hepatic Tissue Engineering. 2014 , 951-986	2
872	New Methods in Tissue Engineering: Improved Models for Viral Infection. 2014 , 1, 475-499	20
871	High-throughput identification of loss-of-function mutations for anti-interferon activity in the influenza A virus NS segment. 2014 , 88, 10157-64	26

870	Determinants for membrane association of the hepatitis C virus NS2 protease domain. 2014 , 88, 6519-23		11
869	Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. 2014 , 88, 8433-44		29
868	A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. <i>PLoS Pathogens</i> , 2014 , 10, e1004064	7.6	51
867	Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. <i>PLoS Pathogens</i> , 2014 , 10, e1004163	7.6	74
866	CD81 and hepatitis C virus (HCV) infection. 2014 , 6, 535-72		61
865	CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. 2014 , 6, 875-92		25
864	Inhibition of hepatitis C virus replication in vitro by xanthohumol, a natural product present in hops. 2014 , 80, 171-6		9
863	Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. <i>PLoS Pathogens</i> , 2014 , 10, e1004424	7.6	264
862	Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. 2014 , 7, 387-98		18
861	Amphipathic Helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. <i>PLoS Pathogens</i> , 2014 , 10, e1004534	7.6	64
860	Aminoterminal amphipathic Helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production. <i>PLoS Pathogens</i> , 2014 , 10, e1004501	7.6	43
859	Unfolded protein response in hepatitis C virus infection. 2014 , 5, 233		41
858	A role for CD81 and hepatitis C virus in hepatoma mobility. 2014 , 6, 1454-72		10
857	Protective immunity against hepatitis C: many shades of gray. 2014 , 5, 274		65
856	Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. 2014 , 6, 1149-87		45
855	Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. 2014 , 5, 545		16
854	A small-molecule inhibitor of hepatitis C virus infectivity. 2014 , 58, 386-96		17
853	A comprehensive functional map of the hepatitis C virus genome provides a resource for probing viral proteins. 2014 , 5, e01469-14		13

852	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. 2014 , 88, 667-78	2
851	The P body protein LSm1 contributes to stimulation of hepatitis C virus translation, but not replication, by microRNA-122. 2014 , 42, 1257-69	19
850	Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. 2014 , 209, 1205-11	63
849	Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells. 2014 , 34, e80-8	9
848	Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. 2014 , 35, 1074-81	12
847	Canine hepacivirus is not associated with chronic liver disease in dogs. 2014 , 21, 223-8	14
846	Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors. 2014 , 57, 350-7	1
845	HCV animal models and liver disease. 2014 , 61, S26-33	34
844	Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1 α /liver-specific PGC-1 β upregulation. 2014 , 88, 8361-74	28
843	A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate. 2014 , 88, 1484-91	23
842	Negative regulation of the interferon response by an interferon-induced long non-coding RNA. 2014 , 42, 10668-80	143
841	The HCV life cycle: in vitro tissue culture systems and therapeutic targets. 2014 , 32, 525-37	22
840	Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus. 2014 , 289, 21276-88	37
839	Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. 2014 , 88, 1433-46	78
838	Mangosteen xanthenes suppress hepatitis C virus genome replication. 2014 , 49, 208-22	16
837	Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. 2014 , 88, 1725-39	37
836	Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein. 2014 , 9, e90333	21
835	The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. 2014 , 5, 550	48

834	Broadly neutralizing antibodies abrogate established hepatitis C virus infection. 2014 , 6, 254ra129	161
833	Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. 2014 , 88, 3678-94	22
832	Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. 2014 , 59, 776-88	67
831	HCV NS5A co-operates with PKR in modulating HCV IRES-dependent translation. 2014 , 26, 113-22	8
830	Kinetic differences in the induction of interferon stimulated genes by interferon- α and interleukin 28B are altered by infection with hepatitis C virus. 2014 , 59, 1250-61	75
829	Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. 2014 , 59, 423-33	35
828	A Novel Human Radixin Peptide Inhibits Hepatitis C Virus Infection at the Level of Cell Entry. 2014 , 20, 269-276	4
827	Hepatitis C virus: a silent killer relevant to dentistry. 2014 , 20, 425-9	2
826	Inhibition of hepatitis C virus infection by NS5A-specific aptamer. 2014 , 106, 116-24	18
825	Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. 2014 , 59, 395-407	58
824	Expression line approach to recombinant human epidermal growth factor into the yeast, <i>Pichia pastoris</i> from Huh-7 cell line. 2014 , 41, 1445-51	2
823	Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection. 2014 , 41, 3813-9	1
822	Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. 2014 , 75, 413-25	31
821	Emerging therapies for the treatment of hepatitis C. 2014 , 6, 4-15	75
820	Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus. 2014 , 22, 354-64	57
819	Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures. 2014 , 95, 423-433	14
818	The past, present and future of neutralizing antibodies for hepatitis C virus. 2014 , 105, 100-11	95
817	Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. 2014 , 88, 5050-61	27

816	Pluripotent stem cell-derived hepatocyte-like cells. 2014 , 32, 504-13	197
815	Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. 2014 , 111, E1264-73	74
814	Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. 2014 , 15, 190-202	82
813	Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. 2014 , 146, 1351-60.e1-4	26
812	Discovery and development of hepatitis C virus NS5A replication complex inhibitors. 2014 , 57, 1643-72	61
811	HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. 2014 , 60, 1170-9	52
810	Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. 2014 , 146, 812-821.e4	51
809	Inhibition of hepatitis C virus production by aptamers against the core protein. 2014 , 88, 1990-9	36
808	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. 2014 , 63, 1137-49	119
807	On the history of hepatitis C virus cell culture systems. 2014 , 57, 1627-42	67
806	Therapeutic vaccines against hepatitis C virus. 2014 , 22, 120-9	17
805	Hepatitis C virus RNA replication and virus particle assembly require specific dimerization of the NS4A protein transmembrane domain. 2014 , 88, 628-42	20
804	Cellular DDX3 regulates Japanese encephalitis virus replication by interacting with viral un-translated regions. <i>Virology</i> , 2014 , 449, 70-81	3.6 55
803	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. 2014 , 60, 1508-18	43
802	Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. 2014 , 59, 375-84	22
801	RACK1 controls IRES-mediated translation of viruses. 2014 , 159, 1086-1095	117
800	Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. 2014 , 24, 1050-66	53
799	Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. 2014 , 5, 5408	54

798	Inhibition of hepatitis C virus replication by chalepin and pseudane IX isolated from <i>Ruta angustifolia</i> leaves. 2014 , 99, 276-83		39
797	Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. 2014 , 88, 10584-97		28
796	Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. 2014 , 162, 140-8		10
795	Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. 2014 , 88, 10280-8		25
794	Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. 2014 , 58, 5386-94		28
793	Virology and cell biology of the hepatitis C virus life cycle: an update. 2014 , 61, S3-S13		116
792	Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells. 2014 , 88, 9233-44		26
791	Antiviral activity of extracts from <i>Morinda citrifolia</i> leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus. 2014 , 58, 188-94		38
790	Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. 2014 , 95, 2468-2479		14
789	RNAi to Treat Chronic Hepatitis C Infection. 2014 , 1-30		
788	The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. <i>Virology</i> , 2014 , 462-463, 34-41	3.6	14
787	MiR-221 accentuates IFN α 's anti-HCV effect by downregulating SOCS1 and SOCS3. <i>Virology</i> , 2014 , 462-463, 343-50	3.6	61
786	Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. 2014 , 147, 1094-105.e25		122
785	Why is it so difficult to develop a hepatitis C virus preventive vaccine?. 2014 , 20 Suppl 5, 103-9		19
784	The elusive function of the hepatitis C virus p7 protein. <i>Virology</i> , 2014 , 462-463, 377-87	3.6	27
783	Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction. 2014 , 88, 11022-33		18
782	New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. 2014 , 60, 1806-8		
781	A unique phosphorylation-dependent eIF4E assembly on 40S ribosomes co-ordinated by hepatitis C virus protein NS5A that activates internal ribosome entry site translation. 2014 , 462, 291-302		7

780	Novel permissive cell lines for complete propagation of hepatitis C virus. 2014 , 88, 5578-94	16
779	HCV NS5A inhibitors: the devil is in the details. 2014 , 147, 273-7	5
778	Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. 2014 , 20, 927-35	106
777	Cell and tissue engineering for liver disease. 2014 , 6, 245sr2	212
776	RacGTPase-activating protein 1 interacts with hepatitis C virus polymerase NS5B to regulate viral replication. 2014 , 454, 19-24	6
775	Lipids and RNA virus replication. 2014 , 9, 45-52	19
774	Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. 2014 , 58, 7416-23	22
773	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. 2014 , 60, 508-20	7
772	Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. 2014 , 88, 12098-111	57
771	Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. 2014 , 57, 5057-71	77
770	Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. 2014 , 26, 78-88	119
769	Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. 2014 , 88, 14278-88	53
768	Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. 2014 , 60, 1551-62	60
767	Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. 2014 , 58, 180-7	82
766	Fusogenic properties of the ectodomains of hepatitis C virus envelope proteins. 2014 , 281, 2558-69	3
765	Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. 2014 , 146, 1373-85.e1-11	116
764	Entry inhibitors and future treatment of hepatitis C. 2014 , 104, 136-42	17
763	Nuclear receptor 4 group A member 1 determines hepatitis C virus entry efficiency through the regulation of cellular receptor and apolipoprotein E expression. 2014 , 95, 1510-1521	6

762	Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN- β 2014 , 192, 6037-44		46
761	Reticulon 3 interacts with NS4B of the hepatitis C virus and negatively regulates viral replication by disrupting NS4B self-interaction. 2014 , 16, 1603-18		27
760	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. <i>Virology</i> , 2014 , 458-459, 190-208	3.6	14
759	MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature. 2014 , 80, 1-12		9
758	Hepatitis C virus life cycle and lipid metabolism. 2014 , 3, 892-921		73
757	A protocol for analyzing hepatitis C virus replication. 2014 , e51362		1
756	Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library. 2014 , 33, 1312-8		5
755	Cell culture-derived HCV cannot infect synovial fibroblasts. 2015 , 5, 18043		1
754	A systematic analysis of a broadly neutralizing antibody AR3C epitopes on Hepatitis C virus E2 envelope glycoprotein and their cross-reactivity. 2015 , 8 Suppl 4, S6		1
753	Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. 2015 , 61, 1136-44		24
752	Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. 2015 , 62, 1059-69		33
751	Advances in drug development for hepatitis C. 2015 , 65, 239-244		2
750	Roles of lipoprotein and apolipoprotein in HCV infection. 2015 , 65, 269-276		1
749	Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. 2015 , 62, 1670-82		15
748	Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region. 2015 , 89, 12245-61		37
747	Inhibitory Effects of Caffeic Acid, a Coffee-Related Organic Acid, on the Propagation of Hepatitis C Virus. 2015 , 68, 268-75		27
746	Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. 2015 , 7, 5746-66		33
745	The evolutionary epidemiology of the hepatitis C virus. 450-472		

744	Hepatitis C. 2015 , 1904-1927.e9		4
743	Exosomes and Their Role in the Life Cycle and Pathogenesis of RNA Viruses. 2015 , 7, 3204-25		145
742	Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. 2015 , 7, 3835-56		23
741	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. 2015 , 7, 3995-4046		38
740	Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection. 2015 , 16, 23683-94		3
739	Molecular characterization and fluorescence analysis of HCV non-structural proteins NS3, NS3-4A and NS4A of genotype 3a. 2015 , 59, 284-94		2
738	TnBP-riton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. 2015 , 10, e0117800		8
737	Deposides: lichen metabolites active against hepatitis C virus. 2015 , 10, e0120405		23
736	Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. 2015 , 10, e0121099		32
735	Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. 2015 , 10, e0121734		9
734	Isolation and characterization of an Huh.7.5.1-derived cell clone highly permissive to hepatitis C virus. 2015 , 68, 81-8		20
733	The Replacement of 10 Non-Conserved Residues in the Core Protein of JFH-1 Hepatitis C Virus Improves Its Assembly and Secretion. 2015 , 10, e0137182		5
732	Survival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume. 2015 , 10, e0139737		16
731	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. 2015 , 10, e0142539		7
730	Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2'-O-Methylation Mutant. <i>PLoS Pathogens</i> , 2015 , 11, e1005345	7.6	35
729	Viral Hepatitis. 2015 , 1439-1468.e7		4
728	Tandem overexpression of five human factors renders murine hepatocytes susceptible to hepatitis C virus. 2015 , 59, 20-6		1
727	Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells. 2015 , 89, 3200-8		9

726	Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?. 2015 , 21, 3786-800	18
725	Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. 2015 , 208, 7-12	15
724	A single-amino-acid mutation in hepatitis C virus NS5A disrupts physical and functional interaction with the transcription factor HNF-1 β . 2015 , 96, 2200-2205	6
723	Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. 2015 , 89, 7758-75	17
722	Inhibition of HCV translation by disrupting the structure and interactions of the viral CRE and 3' X-tail. 2015 , 43, 2914-26	26
721	The hepatitis C virus protein NS3 suppresses TNF α -stimulated activation of NF- κ B by targeting LUBAC. 2015 , 8, ra118	30
720	The way to the peptide vaccine against hepatitis C. 2015 , 9, 217-227	1
719	Hepatitis C virus and lipid droplets: finding a niche. 2015 , 21, 34-42	76
718	Involvement of ERK pathway in interferon alpha-mediated antiviral activity against hepatitis C virus. 2015 , 72, 17-24	8
717	Caffeine inhibits hepatitis C virus replication in vitro. 2015 , 160, 399-407	27
716	Supercritical fluid extraction of heather (<i>Calluna vulgaris</i>) and evaluation of anti-hepatitis C virus activity of the extracts. 2015 , 198, 9-14	15
715	Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. 2015 , 89, 3846-58	50
714	Requirement for chloride channel function during the hepatitis C virus life cycle. 2015 , 89, 4023-9	18
713	Dissecting the roles of the 5' exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication. 2015 , 89, 4857-65	46
712	Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the IFN-related pathway. 2015 , 194, 2757-68	12
711	Phosphatidylserine-specific phospholipase A1 involved in hepatitis C virus assembly through NS2 complex formation. 2015 , 89, 2367-77	22
710	AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. 2015 , 89, 4387-404	72
709	SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection. 2015 , 115, 94-104	23

708	The mechanism of HCV entry into host cells. 2015 , 129, 63-107		75
707	Synthesis and Structure-Activity Relationship of Novel Indole Acrylamide Derivatives as HCV Replication Inhibitors. 2015 , 36, 88-98		6
706	Hepatitis C virus infection of cholangiocarcinoma cell lines. 2015 , 96, 1380-1388		7
705	Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry. 2015 , 96, 1389-1399		3
704	Hepatitis C virus RNA functionally sequesters miR-122. 2015 , 160, 1099-110		246
703	A Dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus. 2015 , 5, 8865		39
702	New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. 2015 , 89, 8346-64		15
701	Development of reverse genetics for Ibaraki virus to produce viable VP6-tagged IBAV. 2015 , 5, 445-53		10
700	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. 2015 , 63, 1323-33		16
699	Disinfection of syringes contaminated with hepatitis C virus by rinsing with household products. 2015 , 2, ofv017		8
698	A conserved NS3 surface patch orchestrates NS2 protease stimulation, NS5A hyperphosphorylation and HCV genome replication. <i>PLoS Pathogens</i> , 2015 , 11, e1004736	7.6	11
697	The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. 2015 , 60, 2232-5		1
696	Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. 2015 , 63, 813-21		26
695	The Molecular Biology of Pestiviruses. 2015 , 93, 47-160		120
694	Spatiotemporal analysis of hepatitis C virus infection. <i>PLoS Pathogens</i> , 2015 , 11, e1004758	7.6	37
693	Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins. <i>PLoS Pathogens</i> , 2015 , 11, e1004817	7.6	22
692	Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. 2015 , 11, 148-57		34
691	The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection. 2015 , 89, 6782-91		4

690	Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. 2015 , 101, 163-78		15
689	HCV envelope glycoproteins in evirion assembly and entry. 2015 , 10, 297-312		4
688	Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection. 2015 , 89, 6805-16		61
687	Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. 2015 , 118, 139-47		44
686	Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication. 2015 , 62, 397-408		26
685	Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells. <i>Virology</i> , 2015 , 481, 223-34	3.6	6
684	Virocidal activity of Egyptian scorpion venoms against hepatitis C virus. 2015 , 12, 47		20
683	Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. 2015 , 10, 1887-96		7
682	Portulaca oleracea L. as a Prospective Candidate Inhibitor of Hepatitis C Virus NS3 Serine Protease. 2015 , 28, 282-9		7
681	Claudins and pathogenesis of viral infection. 2015 , 42, 39-46		7
680	Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice. 2015 , 62, 57-67		16
679	Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. 2015 , 59, 3482-92		19
678	The missing pieces of the HCV entry puzzle. 2015 , 10, 415-428		6
677	Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. 2015 , 89, 6551-61		24
676	Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents. 2015 , 58, 3393-410		44
675	Advances in experimental systems to study hepatitis C virus in vitro and in vivo. <i>Virology</i> , 2015 , 479-480, 221-33	3.6	30
674	Insights into antiviral innate immunity revealed by studying hepatitis C virus. 2015 , 74, 190-7		5
673	Proteomic approaches to analyzing hepatitis C virus biology. 2015 , 15, 2051-65		2

672	Lessons from Reverse Vaccinology for viral vaccine design. 2015 , 11, 89-97	22
671	Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus. 2015 , 23, 618-629	40
670	Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. 2016 , 392, 323-39	36
669	Animal models for the study of HCV. 2015 , 13, 67-74	23
668	Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. 2015 , 59, 7426-36	36
667	Advances in hepatitis C therapies. 2015 , 16, 1929-43	2
666	SEC14L2 enables pan-genotype HCV replication in cell culture. 2015 , 524, 471-5	88
665	A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway. 2015 , 2, 1600-6	31
664	Hepatitis C virus vaccine development: old challenges and new opportunities. 2015 , 2, 285-295	22
663	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. 2015 , 89, 9454-64	15
662	Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase. 2015 , 290, 21857-64	14
661	Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. 2015 , 70, 37-47	23
660	Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model. 2015 , 290, 23173-87	24
659	Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display. 2015 , 2, 859-67	6
658	High-resolution genetic profile of viral genomes: why it matters. 2015 , 14, 62-70	10
657	Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation. 2015 , 89, 11584-602	10
656	Structural and functional genome organization and life cycle of hepatitis C virus. 2015 , 30, 64-70	2
655	Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection. 2015 , 15, 354-364	24

654	Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. 2015 , 10, 2027-53		92
653	Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. 2015 , 62, 541-8		68
652	The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication. <i>Virology</i> , 2015 , 475, 139-49	3.6	10
651	MDA5 plays a critical role in interferon response during hepatitis C virus infection. 2015 , 62, 771-8		70
650	Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. 2015 , 89, 2170-81		62
649	Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genome. 2015 , 148, 616-25		30
648	Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF- κ B signal cascade. 2015 , 356, 470-8		32
647	HCV infection induces the upregulation of miR-221 in NF- κ B dependent manner. 2015 , 196, 135-9		14
646	Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77. 2015 , 89, 811-23		38
645	MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA. 2015 , 35, 1315-23		18
644	HCV J6/JFH1 tilts the capability of myeloid-derived dendritic cells to favor the induction of immunosuppression and Th17-related inflammatory cytokines. 2015 , 32, 741-8		2
643	Regulation of core expression during the hepatitis C virus life cycle. 2015 , 96, 311-321		11
642	Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept. 2015 , 22, 172-80		2
641	NS5B induces up-regulation of the BH3-only protein, BIK, essential for the hepatitis C virus RNA replication and viral release. <i>Virology</i> , 2015 , 474, 41-51	3.6	7
640	Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. 2015 , 61, 460-70		28
639	Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication. 2015 , 64, 957-65		18
638	Hepatitis C Virus. 2016 , 1313-1345		
637	An insight into the molecular characteristics of hepatitis C virus for clinicians. 2016 , 37, 483-91		3

636	MicroRNA-mediated interactions between host and hepatitis C virus. 2016 , 22, 1487-96	37
635	Modeling of HBV and HCV hepatitis with hepatocyte-like cells. 2016 , 8, 97-105	4
634	Status of hepatitis C virus vaccination: Recent update. 2016 , 22, 862-73	15
633	Metabolic alterations and hepatitis C: From bench to bedside. 2016 , 22, 1461-76	69
632	Natural killer cells in hepatitis C: Current progress. 2016 , 22, 1449-60	34
631	HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis. 2016 , 2016, 9012580	43
630	Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy. 2016 , 8,	12
629	Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations. 2016 , 16, 224	6
628	Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. 2016 , 14, e1002421	10
627	Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. 2016 , 11, e0154498	19
626	The Spring Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action. 2016 , 291, 14499-509	8
625	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. 2016 , 22, 324-32	12
624	The expanding toolbox for hepatitis C virus research. 2016 , 23, 320-9	5
623	Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. 2016 , 6, 30627	8
622	ECM proteins in a microporous scaffold influence hepatocyte morphology, function, and gene expression. 2016 , 6, 37427	23
621	A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target. 2016 , 2, e1501535	80
620	Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. 2016 , 129, 55-107	7
619	STAT1 is essential for the inhibition of hepatitis C virus replication by interferon- β but not by interferon- α 2016 , 6, 38336	26

618	Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease. 2016 , 4, 147-156	8
617	Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. 2016 , 6, 25224	8
616	Hepatitis C: a successful story of cure. 2016 , 61, 1884-1887	1
615	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. 2016 , 90, 5549-5560	22
614	New combination antiviral for the treatment of hepatitis C. 2016 , 73, 1042-50	2
613	The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. 2016 , 291, 12294-309	20
612	Release of Infectious Hepatitis C Virus from Huh7 Cells Occurs via a trans-Golgi Network-to-Endosome Pathway Independent of Very-Low-Density Lipoprotein Secretion. 2016 , 90, 7159-70	35
611	Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. 2016 , 60, 3563-78	24
610	Experimental models of hepatitis B and C - new insights and progress. 2016 , 13, 362-74	52
609	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. 2016 , 60, 3786-93	29
608	Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis. 2016 , 90, 6387-6400	75
607	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. 2016 , 13, 338-51	122
606	Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. <i>Virology</i> , 2016 , 494, 236-47	3.6 14
605	Induced pluripotent stem cells: A new addition to the virologists armamentarium. 2016 , 235, 191-195	2
604	Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. 2016 , 22, 826-832	47
603	Human Choline Kinase-IPromotes Hepatitis C Virus RNA Replication through Modulation of Membranous Viral Replication Complex Formation. 2016 , 90, 9075-95	6
602	A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. 2016 , 90, 10499-10512	10
601	Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA Clone. 2016 , 1,	78

600	The Intracellular Cholesterol Transport Inhibitor U18666A Inhibits the Exosome-Dependent Release of Mature Hepatitis C Virus. 2016 , 90, 11181-11196	55
599	Quantitative Lipid Droplet Proteome Analysis Identifies Annexin A3 as a Cofactor for HCV Particle Production. 2016 , 16, 3219-3231	31
598	Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma. 2016 , 78, 315-326	12
597	Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System. 2016 , 90, 9058-74	18
596	Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation. 2016 , 90, 8464-77	12
595	MEAN inhibits hepatitis C virus replication by interfering with a polypyrimidine tract-binding protein. 2016 , 20, 1255-65	3
594	Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. 2016 , 173, 191-211	29
593	Affinity Purification of the Hepatitis C Virus Replicase Identifies Valosin-Containing Protein, a Member of the ATPases Associated with Diverse Cellular Activities Family, as an Active Virus Replication Modulator. 2016 , 90, 9953-9966	20
592	Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. 2016 , 132, 287-95	16
591	Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection. 2016 , 90, 9632-9643	30
590	Purification of infectious and non-infectious chlamydial particles using iodixanol for density gradient preparation. 2016 , 128, 20-23	1
589	Hepatitis C and Hepatocellular Carcinoma. 2016 , 261-273	
588	Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. 2016 , 64, 1495-1506	7
587	Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. 2016 , 6, 36619	9
586	The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. 2016 , 65, S2-S21	143
585	Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. 2016 , 90, 10486-10498	48
584	Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. 2016 , 151, 973-985.e2	61
583	Kushenin induces the apoptosis of HCV-infected cells by blocking the PI3K-Akt-mTOR pathway via inhibiting NS5A. 2016 , 345, 108-14	2

582	Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. 2016 , 64, 1881-1892	48
581	An Atypical System for Studying Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. 2016 , 6, 26282	4
580	Three-dimensional cell culture models for investigating human viruses. 2016 , 31, 363-379	17
579	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. 2016 , 7,	8
578	MAIT cells are activated during human viral infections. 2016 , 7, 11653	283
577	The Strange, Expanding World of Animal Hepaciviruses. 2016 , 3, 53-75	53
576	Hepatitis C Virus I. 2016 ,	2
575	Lipid and Lipoprotein Components Play Important Roles the Egress and Infectivity of Hepatitis C Virions. 2016 , 255-272	0
574	HCV Receptors and Virus Entry. 2016 , 81-103	2
573	Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment. 2016 , 7,	37
572	The 2016 Lasker-DeBaKey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure. 2016 , 59, 1198-1201	0
571	Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. 2016 , 22, 287-97	22
570	Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. 2016 , 90, 7456-7468	9
569	Completion of the Entire Hepatitis C Virus Life Cycle in Vero Cells Derived from Monkey Kidney. 2016 , 7,	13
568	HCV NS4B targets Scribble for proteasome-mediated degradation to facilitate cell transformation. 2016 , 37, 12387-12396	6
567	Viral Determinants of miR-122-Independent Hepatitis C Virus Replication. 2016 , 1,	20
566	Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. 2016 , 113, 7620-5	40
565	Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection. 2016 , 88, 1791-803	

564	Effect of Hepatitis C virus proteins on the production of proinflammatory and profibrotic cytokines in Huh7.5 human hepatoma cells. 2016 , 50, 422-430	4
563	Hepatitis C virus NS5A protein interacts with lysine methyltransferase SET and MYND domain-containing 3 and induces activator protein 1 activation. 2016 , 60, 407-17	6
562	Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication. 2016 , 18, 1121-33	26
561	Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus. 2016 , 291, 1974-1990	33
560	Quasispecies: From Theory to Experimental Systems. 2016 ,	27
559	Viral Fitness as a Measure of Adaptation. 2016 , 169-195	1
558	Quasispecies Dynamics in Disease Prevention and Control. 2016 , 263-297	3
557	Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. 2016 , 7, 10631	38
556	Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81. 2016 , 37, 836-42	5
555	Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions. 2016 , 129, 39-46	7
554	Fabrication of flexible self-standing all-cellulose nanofibrous composite membranes for virus removal. 2016 , 143, 9-17	30
553	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. 2016 , 90, 5075-5089	4
552	Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis. 2016 , 113, 2484-9	52
551	The deletion of residues 268-292 of E1 impairs the ability of HCV envelope proteins to induce pore formation. 2016 , 217, 63-70	5
550	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. 2016 , 90, 33-42	11
549	Phosphoproteomics Identified an NS5A Phosphorylation Site Involved in Hepatitis C Virus Replication. 2016 , 291, 3918-31	19
548	A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. 2015 , 90, 3288-301	47
547	HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. 2016 , 65, 1988-1997	32

546	Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients. 2016 , 90, 992-1008	9
545	High-throughput approaches to unravel hepatitis C virus-host interactions. 2016 , 218, 18-24	6
544	Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. 2016 , 150, 206-217.e4	52
543	Interleukin 17, Produced by $\gamma\delta$ Cells, Contributes to Hepatic Inflammation in a Mouse Model of Biliary Atresia and Is Increased in Livers of Patients. 2016 , 150, 229-241.e5	44
542	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 2016 , 64, 29-36	26
541	HCV infection, IFN response and the coding and non-coding host cell genome. 2016 , 212, 85-102	14
540	Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. 2017 , 8, 13882	27
539	RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP. 2017 , 7, 41452	14
538	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. 2017 , 16, S75-S91	40
537	Flavivirus Infection Uncouples Translation Suppression from Cellular Stress Responses. 2017 , 8,	60
536	Anti-HCV Activity from Semi-purified Methanolic Root Extracts of <i>Valeriana wallichii</i> . 2017 , 31, 433-440	13
535	Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors and. 2017 , 61,	5
534	Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. 2017 , 91,	32
533	Hepatitis C virus - Associated marginal zone lymphoma. 2017 , 30, 41-49	12
532	Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. 2017 , 53, 151-164	14
531	Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism. 2017 , 90, 352-367	5
530	Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. 2017 , 91,	19
529	Sensitive luminescent reporter viruses reveal appreciable release of hepatitis C virus NS5A protein into the extracellular environment. <i>Virology</i> , 2017 , 507, 20-31	3.6 12

528	Efficient replication of blood-borne hepatitis C virus in human fetal liver stem cells. 2017 , 66, 1045-1057	6
527	Notch Signaling Regulates Circulating T Helper 22 Cells in Patients with Chronic Hepatitis C. 2017 , 30, 522-532	14
526	Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver. 2017 , 9, 816-834	28
525	Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics. 2017 , 246, 42-50	1
524	Signalome-wide assessment of host cell response to hepatitis C virus. 2017 , 8, 15158	10
523	Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons. 2017 , 153, 566-578.e5	11
522	CelluSponge and Go Matrix as innovative three-dimensional cell culture platforms. 2017 , 250-283	2
521	A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner. 2017 , 7, 44676	14
520	Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly. 2017 , 141, 62-69	28
519	Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus. 2017 , 137, 247-262	12
518	Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity. 2017 , 7, 45228	5
517	Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. 2017 , 61,	9
516	Synthesis and biological evaluation of novel anti-hepatitis C virus (HCV) agents: 2-hydroxyphenethyl sulfanyl-oxopyrimidines. 2017 , 26, 1388-1396	0
515	An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry. 2017 , 91,	10
514	Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo. 2017 , 91,	15
513	Green fluorescent protein-tagged apolipoprotein E: A useful marker for the study of hepatic lipoprotein egress. 2017 , 18, 192-204	5
512	Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. 2017 , 292, 21676-21689	22
511	Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b. 2017 , 21, 431-441	21

510	The potential of signal peptide peptidase as a therapeutic target for hepatitis C. 2017 , 21, 827-836	2
509	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. 2017 , 147, 19-28	18
508	Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibitor. 2017 , 140, 65-73	7
507	A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry. 2017 , 11, 440-445	11
506	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. 2017 , 91,	15
505	Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric Mice. 2017 , 4, 405-417	3
504	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. 2017 , 240, 35-46	2
503	Development of Hepatocyte-like Cell Derived from Human Induced Pluripotent Stem cell as a Host for Clinically Isolated Hepatitis C Virus. 2017 , 42, 4A.13.1-4A.13.34	3
502	Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4 T cells contributes to viral persistence in chronic hepatitis C. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 94, 386-393	7.5 12
501	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. 2017 , 8, 1789	44
500	An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. 2017 , 50, 87-94	22
499	Low-molecular-weight regulators of biogenic polyamine metabolism affect cytokine production and expression of hepatitis C virus proteins in Huh7.5 human hepatocarcinoma cells. 2017 , 51, 453-464	3
498	Hepatitis C Virus NS5A Targets Nucleosome Assembly Protein NAP1L1 To Control the Innate Cellular Response. 2017 , 91,	14
497	The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles. 2017 , 292, 13702-13713	52
496	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. 2017 , 152, 257-270.e7	26
495	microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: function in replication and influence of RNA secondary structure. 2017 , 74, 747-760	25
494	Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System. 2017 , 91,	20
493	Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. 2017 , 11, 1600089	8

492	Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging. 2017 , 66, 55-66		15
491	New potent biaryl sulfate-based hepatitis C virus inhibitors. 2017 , 125, 87-100		4
490	Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. 2017 , 66, 357-370		9
489	Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo. 2017 , 98, 2069-2078		22
488	Protein Inhibitor of Activated STAT2 Restricts HCV Replication by Modulating Viral Proteins Degradation. 2017 , 9,		10
487	The Mechanism of Synchronous Precise Regulation of Two Shrimp White Spot Syndrome Virus Targets by a Viral MicroRNA. 2017 , 8, 1546		13
486	Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. 2017 , 8, 2413		18
485	Oxidative Stress in Liver Diseases. 2017 , 125-140		0
484	HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. 2017 , 12, e0181683		13
483	Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. <i>PLoS Pathogens</i> , 2017 , 13, e1006214	7.6	21
482	Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. 2017 , 98, 962-976		5
481	Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. 2018 , 92,		9
480	Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. 2018 , 97, e0208		10
479	Hepatitis C Virus Infection and Vaccine Development. 2018 , 8, 195-204		12
478	Positive-sense RNA viruses reveal the complexity and dynamics of the cellular and viral epitranscriptomes during infection. 2018 , 46, 5776-5791		61
477	HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. 2018 , 154, 1791-1804.e22		88
476	Genetic Analysis of Serum-Derived Defective Hepatitis C Virus Genomes Revealed Novel Viral Elements for Virus Replication and Assembly. 2018 , 92,		7
475	Interleukin-7 augments CD8 T cells function and promotes viral clearance in chronic hepatitis C virus infection. 2018 , 102, 26-33		12

474	Engineered Livers for Infectious Diseases. 2018 , 5, 131-144			28
473	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. 2018 , 154, 1435-1448	61		
472	Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1 α via Chaperone-Mediated Autophagy. 2018 , 92,			15
471	HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. 2018 , 154, 2194-2208.	e12		34
470	Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes. 2018 , 154, 2237-2251.	e16		36
469	Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). <i>Virology</i> , 2018 , 518, 253-263		3.6	6
468	Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release. 2018 , 9,			21
467	Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. 2018 , 92,			21
466	Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. 2018 , 8, 4619			25
465	Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs. 2018 , 217, 466-473			9
464	Novel Synthesis and Phenotypic Analysis of Mutant Clouds for Hepatitis E Virus Genotype 1. 2018 , 92,			3
463	Exosomes Mediate Intercellular Transmission of Porcine Reproductive and Respiratory Syndrome Virus. 2018 , 92,			32
462	NS3 from Hepatitis C Virus Strain JFH-1 Is an Unusually Robust Helicase That Is Primed To Bind and Unwind Viral RNA. 2018 , 92,			9
461	Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus. 2018 , 25, 63-71			1
460	Resistance-Associated Substitutions/Variants Correlate to Therapeutic Outcomes of Novel Direct-Acting Antivirals in Different HCV Genotype Treated Individuals. 2018 ,			0
459	The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry. 2018 , 3, 1369-1376			33
458	Cyclophilin A as a target in the treatment of cytomegalovirus infections. 2018 , 26, 2040206618811413			4
457	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. 2018 , 24, 717-730.	e5		47

456	The Role of Tissue Oxygen Tension in Dengue Virus Replication. 2018 , 7,	12
455	Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. 2018 , 9, 2950	2
454	High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. 2018 , 8, 17505	5
453	The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. 2018 , 19,	30
452	Glycogen Synthase Kinase 3 β Enhances Hepatitis C Virus Replication by Supporting miR-122. 2018 , 9, 2949	10
451	Hepatitis C virus: Morphogenesis, infection and therapy. 2018 , 10, 186-212	55
450	Cytokine-Modulated Natural Killer Cells Differentially Regulate the Activity of the Hepatitis C Virus. 2018 , 19,	3
449	Potent suppression of HIV-1 cell attachment by Kudzu root extract. 2018 , 15, 64	14
448	GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals. 2018 , 8, 14329	3
447	A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages. <i>PLoS Pathogens</i> , 2018 , 14, e1007307	7.6 13
446	Rare haplotype load as marker for lethal mutagenesis. 2018 , 13, e0204877	4
445	Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. 2018 , 9, 2146	31
444	Defining Breadth of Hepatitis C Virus Neutralization. 2018 , 9, 1703	8
443	Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.. 2018 , 8, 31803-31821 ⁵	5
442	Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. 2018 , 46, 835-852	12
441	Transmission genetics of drug-resistant hepatitis C virus. <i>ELife</i> , 2018 , 7,	8.9 3
440	Hepatitis C Virus Infection of Cultured Cells and Primary Human Hepatocytes. 2018 , 80, e54	1
439	Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. 2018 , 158, 264-287	27

438	Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. <i>Virology</i> , 2018 , 522, 177-192	3.6	3
437	Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds. 2018 , 23,		2
436	Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. 2018 , 92,		3
435	Animal Models to Study Hepatitis C Virus Infection. 2018 , 9, 1032		23
434	Signals Involved in Regulation of Hepatitis C Virus RNA Genome Translation and Replication. 2018 , 9, 395		25
433	Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars. 2018 , 23,		3
432	CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling. 2018 , 68, 1710-1725		13
431	Sequential S232/S235/S238 Phosphorylation of the Hepatitis C Virus Nonstructural Protein 5A. 2018 , 92,		11
430	Adapted HCV JFH1 variant is capable of accommodating a large foreign gene insert and allows lower level HCV replication and viral production. 2018 , 14, 1211-1220		
429	Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection. 2018 , 13, e0202524		3
428	HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A. <i>PLoS Pathogens</i> , 2018 , 14, e1007177	7.6	19
427	Resistance of high fitness hepatitis C virus to lethal mutagenesis. <i>Virology</i> , 2018 , 523, 100-109	3.6	18
426	Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. 2018 , 7,		14
425	Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement. 2018 , 7, 143		1
424	Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor. 2018 , 23,		2
423	Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication. 2018 , 259, 10-17		
422	A role for domain I of the hepatitis C virus NS5A protein in virus assembly. <i>PLoS Pathogens</i> , 2018 , 14, e1006834	7.6	23
421	Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. 2019 , 219, 68-79		10

420	Hepatitis C virus infection increases autophagosome stability by suppressing lysosomal fusion through an Arl8b-dependent mechanism. 2019 , 294, 14257-14266	7
419	Emerging Role of L-Dopa Decarboxylase in Flaviviridae Virus Infections. 2019 , 8,	10
418	Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. 2019 , 10, 3468	62
417	Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. 2019 , 2019, 9605252	5
416	The remarkable history of the hepatitis C virus. 2019 , 21, 263-270	4
415	Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection. 2019 , 20, 753-773	1
414	Notch signaling suppresses CD14 monocytes cells activity in patients with chronic hepatitis C. 2019 , 127, 642-652	3
413	Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. 2019 , 171, 104612	4
412	The Hepatitis C Virus Replicon System and Its Role in Drug Development. 2019 , 69-96	1
411	The Method of Cutting Image of Vehicle Face based on Haar Feature and Improved Cascade Classifier. 2019 , 1335, 012018	0
410	P-6.3: The Impact of Thin Film Shadow on Organic Light - Emitting Diode Flexible Encapsulation. 2019 , 50, 759-760	
409	Hepatitis C Virus: 30 Years after Its Discovery. 2019 , 9,	7
408	Plant-Derived Purification, Chemical Synthesis, and In Vitro/In Vivo Evaluation of a Resveratrol Dimer, Viniferin, as an HCV Replication Inhibitor. 2019 , 11,	10
407	Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. 2019 , 11,	36
406	Polymorphic assembly of virus-capsid proteins around DNA and the cellular uptake of the resulting particles. 2019 , 307, 342-354	14
405	A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. 2019 , 472, 65-74	8
404	Water-soluble extracts from edible mushrooms (<i>Agaricus bisporus</i>) as inhibitors of hepatitis C viral replication. 2019 , 10, 3758-3767	10
403	HCV Molecular Virology and Animal Models. 2019 , 29-68	1

402	Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. 2019 , 10, 2073		13
401	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. <i>PLoS Pathogens</i> , 2019 , 15, e1007772	7.6	24
400	The remarkable history of the hepatitis C virus. 2019 , 20, 436-446		14
399	Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. 2019 , 138, 156-171		5
398	Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. 2019 , 116, 10039-10047		22
397	Long-term functional maintenance of primary human hepatocytes in vitro. <i>Science</i> , 2019 , 364, 399-402	33.3	82
396	The Role of ApoE in HCV Infection and Comorbidity. 2019 , 20,		7
395	Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. <i>Antiviral Therapy</i> , 2019 , 24, 371-381	1.6	2
394	Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes. 2019 , 71, 52-61		18
393	Building a mechanistic mathematical model of hepatitis C virus entry. 2019 , 15, e1006905		12
392	TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response. 2019 , 42, 1317-1325		8
391	Probing and pressing surfaces of hepatitis C virus-like particles. 2019 , 545, 259-268		13
390	Counteraction of HCV-Induced Oxidative Stress Concurs to Establish Chronic Infection in Liver Cell Cultures. 2019 , 2019, 6452390		16
389	Taming a beast: lessons from the domestication of hepatitis C virus. 2019 , 35, 27-34		6
388	Establishment of serum derived infectivity coculture model for enhancement of hepatitis C virus replication in vitro. 2019 , 27, 185-191		1
387	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. 2019 , 70, 771-787		28
386	Is the conquest of Hepatitis C imminent?. 2019 , 21, e3		1
385	Influence of Tattoo Ink on Hepatitis C Virus Infectiousness. 2019 , 6, ofz047		1

384	MARCH8 Ubiquitinates the Hepatitis C Virus Nonstructural 2 Protein and Mediates Viral Envelopment. 2019 , 26, 1800-1814.e5	24
383	A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. 2019 , 93,	7
382	Cell Culture Systems of HCV Using JFH-1 and Other Strains. 2019 , 9,	6
381	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. 2019 , 11,	5
380	Serine 229 Balances the Hepatitis C Virus Nonstructural Protein NS5A between Hypo- and Hyperphosphorylated States. 2019 , 93,	3
379	Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. 2019 , 82, 368-374	7
378	The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity. 2019 , 2019, 3124745	4
377	The Host Factor Erlin-1 is Required for Efficient Hepatitis C Virus Infection. 2019 , 8,	6
376	HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. 2019 , 70, 388-397	25
375	Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. 2019 , 93,	14
374	Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein. 2019 , 93,	11
373	Molecular identification and characterization of nonprimate hepaciviruses in equines. 2019 , 164, 391-400	4
372	Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. 2019 , 208, 3-24	11
371	Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. <i>Virology</i> , 2020 , 540, 132-140	3.6 7
370	How do interruptions affect user contributions on social commerce?. 2020 , 30, 535-565	3
369	Viral fitness as a measure of adaptation. 2020 , 167-194	0
368	Quasispecies dynamics in disease prevention and control. 2020 , 263-299	
367	Hepatitis B Virus Infection. 2020 ,	0

366	Hepatitis C Virus Structure: Defined by What It Is Not. 2020 , 10,	6
365	Core-Shell-Heterostructured Magnetic-Plasmonic Nanoassemblies with Highly Retained Magnetic-Plasmonic Activities for Ultrasensitive Bioanalysis in Complex Matrix. 2020 , 7, 1902433	16
364	Altered mA Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. 2020 , 77, 542-555.e8	66
363	Antivirale Therapie [Mechanismen, Substanzen, Anwendung. 2020 , 15, 135-150	
362	Transcriptome and miRNome Analysis Provide New Insight Into Host Lipid Accumulation, Innate Immunity, and Viral Persistence in Hepatitis C Virus Infection. 2020 , 11, 535673	2
361	An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles. 2020 , 589, 119826	6
360	Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. 2020 , 10, 16261	11
359	Antigen glycosylation broadens the immunogenicity of E2 subunit HCV vaccines. 2020 , 5, 17-17	
358	Sequential Phosphorylation of the Hepatitis C Virus NS5A Protein Depends on NS3-Mediated Autocleavage between NS3 and NS4A. 2020 , 94,	2
357	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. 2020 , 15, e0236447	3
356	Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma. 2020 , 18, e3000562	2
355	Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection. 2020 , 11, 1756	9
354	ISGylation of Hepatitis C Virus NS5A Protein Promotes Viral RNA Replication via Recruitment of Cyclophilin A. 2020 , 94,	7
353	Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. 2020 , 64,	5
352	Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. 2020 , 6, eabb5938	9
351	Cholesterol sensing by CD81 is important for hepatitis C virus entry. 2020 , 295, 16931-16948	6
350	Systematic review of the antiviral properties of TRIM56: a potential therapeutic intervention for COVID-19. 2020 , 16, 973-984	2
349	Synthetic retinoid AM80 inhibits IL-17 production of gamma delta T cells and ameliorates biliary atresia in mice. 2020 , 40, 3031-3041	3

348	Virus spread in the liver: mechanisms, commonalities, and unanswered questions. 2020 , 15, 707-715	2
347	Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks. 2020 , 9,	9
346	The 2020 Nobel Prize in Physiology or Medicine. 2020 , 63, 13197-13204	1
345	IL-1 β Enhances the Antiviral Effect of IFN- γ on HCV Replication by Negatively Modulating ERK2 Activation. 2020 , 6, 1708-1718	3
344	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. 2020 , 63, 5972-5989	5
343	A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection. 2020 , 11, 725	8
342	Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. 2020 , 8,	5
341	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. <i>PLoS Pathogens</i> , 2020 , 16, e1008554	7.6 10
340	Controlled Functional Zonation of Hepatocytes by Engineering of Wnt Signaling. 2020 , 9, 1638-1649	4
339	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. 2020 , 27, 780-792.e5	9
338	Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships. 2020 , 14, 757-771	2
337	Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases. 2020 , 14, 2569-2574	61
336	Effect of P-body component Mov10 on HCV virus production and infectivity. 2020 , 34, 9433-9449	4
335	Hepatitis C virus NS3-4A protease regulates the lipid environment for RNA replication by cleaving host enzyme 24-dehydrocholesterol reductase. 2020 , 295, 12426-12436	6
334	Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis. 2020 , 821-850	1
333	Inhibition of hepatitis C virus genotype 4 replication using siRNA targeted to the viral core region and the CD81 cellular receptor. 2020 , 25, 345-355	6
332	In Vitro Hepatitis C Virus Infection and Hepatic Choline Metabolism. 2020 , 12,	4
331	Viral replicons as valuable tools for drug discovery. 2020 , 25, 1026-1033	6

330	Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. 2020 , 64,	7
329	Syndecan 4 Upregulation on Activated Langerhans Cells Counteracts Langerin Restriction to Facilitate Hepatitis C Virus Transmission. 2020 , 11, 503	3
328	Hepatitis C Virus Translation Regulation. 2020 , 21,	14
327	Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations. 2020 , 94,	1
326	Broad and Dynamic Diversification of Infectious Hepatitis C Virus in a Cell Culture Environment. 2020 , 94,	12
325	HCV Assembly and Egress via Modifications in Host Lipid Metabolic Systems. 2021 , 11,	7
324	Public funding for transformative drugs: the case of sofosbuvir. 2021 , 26, 273-281	2
323	Role of Exosomes in Biological Communication Systems. 2021 ,	2
322	Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum. 2021 , 296, 100018	1
321	Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. 2021 , 6, 7	1
320	Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. 2021 , 102,	9
319	Three-Dimensional Cell Culture Systems for Studying Hepatitis C Virus. 2021 , 13,	2
318	Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1-3 Strains and Does Not Correlate with Virus Replication. 2021 , 13,	1
317	TGF- β isoforms inhibit hepatitis C virus propagation in transforming growth factor beta/SMAD protein signalling pathway dependent and independent manners. 2021 , 25, 3498-3510	6
316	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. 2021 , 9,	2
315	Hepatitis C Viral Replication Complex. 2021 , 13,	3
314	A two-level, dynamic fitness landscape of hepatitis C virus revealed by self-organized haplotype maps.	1
313	Quantifying the Evolutionary Constraints and Potential of Hepatitis C Virus NS5A Protein. 2021 , 6,	1

312	To Explore the Potential Targets and Current Structure-based Design Strategies Utilizing Co-crystallized Ligand to Combat HCV. 2021 , 22, 590-604	1
311	Hepatitis C Virus Uses Host Lipids to Its Own Advantage. 2021 , 11,	3
310	HCV spread kinetics reveal varying contributions of transmission modes to infection dynamics.	
309	HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4. 2021 ,	2
308	Bile Goes Viral. 2021 , 13,	3
307	HCV virology and diagnosis. 2021 , 45, 101626	7
306	Role of Ras-related Nuclear Protein/Polypyrimidine Tract Binding Protein in Facilitating the Replication of Hepatitis C Virus. 2021 , 9, 458-465	
305	Photo-catalyzed TiO inactivates pathogenic viruses by attacking viral genome. 2021 , 414, 128788	16
304	Differentiated Cells in Prolonged Hypoxia Produce Highly Infectious Native-Like Hepatitis C Virus Particles. 2021 , 74, 627-640	0
303	Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. 2021 , 65, e0009721	20
302	Investigating virus-host cell interactions: Comparative binding forces between hepatitis C virus-like particles and host cell receptors in 2D and 3D cell culture models. 2021 , 592, 371-384	3
301	In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. <i>PLoS Pathogens</i> , 2021 , 17, e1009720	7.6 1
300	Cellular factors involved in the hepatitis C virus life cycle. 2021 , 27, 4555-4581	1
299	KETONURIAAN EARLY COVID-19 SEVERITY & PROGNOSTIC MARKER? AN OBSERVATIONAL STUDY.. 2021 , 36-38	
298	Hepatitis C virus genotype 4: A poorly characterized endemic genotype. 2021 , 93, 6079-6088	2
297	Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. 2021 , 16, e0255336	0
296	Glycometabolism regulates hepatitis C virus release. <i>PLoS Pathogens</i> , 2021 , 17, e1009746	7.6 1
295	HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics. 2021 , 13,	0

- 294 Retinoic Acid-Inducible Gene I-Like Receptors Activate Snail To Limit RNA Viral Infections. **2021**, 95, e0121621 o
- 293 Two New Purification Methods of Hepatitis C Virus Particles from Serum-Free Culture System. **2021**, 21, o
- 292 Untargeted Metabolic Profiling of Extracellular Vesicles of SARS-CoV-2-Infected Patients Shows Presence of Potent Anti-Inflammatory Metabolites. **2021**, 22, 2
- 291 4?-Selenonucleosides: Regio- and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti-Hepatitis C Virus (HCV) Agents.
- 290 HCV egress - unconventional secretion of assembled viral particles. **2021**, 1
- 289 Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. **2021**, 40, e106765 4
- 288 A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. **2021**, 9, e0043921 1
- 287 Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB/c Mice. **2021**, 2021, 3108157 o
- 286 iPSCs for modeling hepatotropic pathogen infections. **2021**, 149-213 o
- 285 Hepatitis C virus: propagation, quantification, and storage. **2010**, Chapter 15, Unit 15D.1 12
- 284 Hepatitis Virus Resistance. **2008**, 291-323 1
- 283 Hepatic Tissue Engineering. **2011**, 321-342 5
- 282 Hepatitis C Virus and Hepatocellular Carcinoma. **2012**, 571-583 2
- 281 Application of Deep Mutational Scanning in Hepatitis C Virus. **2019**, 1911, 183-190 1
- 280 Functional Characterization of Apolipoproteins in the HCV Life Cycle. **2019**, 1911, 235-246 2
- 279 Investigating Hepatitis C Virus Infection Using Super-Resolution Microscopy. **2019**, 1911, 247-261 1
- 278 Live Cell Imaging of Hepatitis C Virus Trafficking in Hepatocytes. **2019**, 1911, 263-274 4
- 277 Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. **2019**, 1911, 275-294 3

276	Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV. 2019 , 1911, 33-45	5
275	Monitoring of Interferon Response Triggered by Cells Infected by Hepatitis C Virus or Other Viruses Upon Cell-Cell Contact. 2019 , 1911, 319-335	2
274	In Vitro Neutralization Assay Using Cultured Hepatitis C Virus. 2019 , 1911, 433-439	4
273	Mice with Chimeric Human Livers and Their Applications. 2019 , 1911, 459-479	4
272	Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies. 2019 , 1911, 481-503	4
271	InFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular Clones. 2019 , 1911, 93-104	1
270	Mechanisms of Hepatitis C Virus Drug Resistance. 2009 , 531-545	1
269	Studying HCV cell entry with HCV pseudoparticles (HCVpp). 2009 , 510, 279-93	34
268	Screening of small-molecule compounds as inhibitors of HCV entry. 2009 , 510, 295-304	22
267	Isolation of JFH-1 strain and development of an HCV infection system. 2009 , 510, 305-27	24
266	Measuring HCV infectivity produced in cell culture and in vivo. 2009 , 510, 329-36	76
265	Genotype 1a HCV (H77S) infection system. 2009 , 510, 337-46	10
264	Full-length infectious HCV chimeras. 2009 , 510, 347-59	7
263	Adaptation of the hepatitis C virus to cell culture. 2009 , 510, 361-72	14
262	In vivo study of HCV in mice with chimeric human livers. 2009 , 510, 383-99	11
261	Hepatitis C and Hepatocellular Carcinoma. 2009 , 259-281	4
260	Use of human hepatocytes to investigate HCV infection. 2010 , 640, 447-62	5
259	The Structure of HCV. 2016 , 31-64	1

258	Cell Culture Models and Animal Models for HBV Study. 2020 , 1179, 109-135	11
257	Diagnosis, Management and Disease Mechanisms of Hepatitis in the Era of Genomic Medicine. 2009 , 1375-1389	1
256	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. 2017 , 553-627	0
255	Introduction to Viruses and Viral Diseases. 2010 , 1905-1921	2
254	Hepatitis C. 2010 , 2157-2185	4
253	Hepatitis C virus vaccines. 2008 , 1187-1199	1
252	Replication of Hepatitis C Virus. 2012 , 97-110	1
251	Biology of Viruses and Viral Diseases. 2015 , 1681-1693.e4	3
250	Infectious Agents. 2006 , 507-548	8
249	HCV upregulates Bim through the ROS/JNK signalling pathway, leading to Bax-mediated apoptosis. 2015 , 96, 2670-2683	17
248	Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. 2016 , 97, 82-94	14
247	Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. 2016 , 97, 1381-1394	17
246	Calsyntenin-1 mediates hepatitis C virus replication. 2016 , 97, 1877-1887	4
245	Flexible and rapid construction of viral chimeras applied to hepatitis C virus. 2016 , 97, 2187-2193	11
244	Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. 2016 , 97, 2265-2279	30
243	Hepatitis C virus replicative double-stranded RNA is a potent interferon inducer that triggers interferon production through MDA5. 2016 , 97, 2868-2882	15
242	Cooperative enhancement of translation by two adjacent microRNA-122/Argonaute 2 complexes binding to the 5' untranslated region of hepatitis C virus RNA. 2017 , 98, 212-224	11
241	Aggregation of a hepatitis C virus replicase module induced by ablation of p97/VCP. 2017 , 98, 1667-1678	11

240	Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a. 2018 , 99, 1066-1077	9
239	Replicase-mediated shielding of the poliovirus replicative double-stranded RNA to avoid recognition by MDA5. 2018 , 99, 1199-1209	6
238	Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells. 2018 , 99, 1407-1417	3
237	mTORC1 restricts hepatitis C virus RNA replication through ULK1-mediated suppression of miR-122 and facilitates post-replication events. 2020 , 101, 86-95	11
236	Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. 2019 , 68, 642-648	1
235	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. 2009 , 90, 48-58	147
234	Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. 2010 , 91, 122-32	72
233	Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. 2011 , 92, 494-506	31
232	Characterization of hepatitis C RNA-containing particles from human liver by density and size. 2008 , 89, 2507-2517	44
231	Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. 2006 , 87, 861-871	37
230	A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells. 2006 , 87, 3587-3598	6
229	Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. 2007 , 88, 2495-2503	128
228	Adaptive potential of a drug-targeted viral protein as a function of environmental stress.	1
227	Dissimilar conservation pattern in hepatitis C virus mutant spectra, consensus sequences, and data banks.	2
226	Infection and transmission of SARS-CoV-2 depends on heparan sulfate proteoglycans.	5
225	Antibody Responses in Hepatitis C Infection. 2021 , 11,	4
224	Nucleoside Analog Inhibitors of Hepatitis C Viral Replication. 153-166	2
223	Hepatitis C Virus. 1599-1616	1

222	Synergistic lethal mutagenesis of hepatitis C virus. 2019 ,	7
221	Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. 2011 , 121, 37-56	260
220	Emerging concepts in immunity to hepatitis C virus infection. 2013 , 123, 4121-30	73
219	Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award. 2016 , 126, 3639-3644	3
218	A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. 2017 , 2, 82	13
217	The CD81 partner EWI-2wint inhibits hepatitis C virus entry. 2008 , 3, e1866	82
216	Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. 2008 , 3, e2660	60
215	Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. 2009 , 4, e4233	99
214	Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. 2009 , 4, e6561	47
213	Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. 2010 , 5, e9815	79
212	Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature. 2011 , 6, e22808	18
211	Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. 2011 , 6, e26637	40
210	Innate host response in primary human hepatocytes with hepatitis C virus infection. 2011 , 6, e27552	25
209	A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. 2012 , 7, e44965	23
208	Production, purification and characterization of recombinant, full-length human claudin-1. 2013 , 8, e64517	9
207	Phenotypic and genotypic characteristics of novel mouse cell line (NIH/3T3)-adapted human enterovirus 71 strains (EV71:TLLm and EV71:TLLmv). 2014 , 9, e92719	9
206	Visualization and analysis of hepatitis C virus structural proteins at lipid droplets by super-resolution microscopy. 2014 , 9, e102511	17
205	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. 2015 , 10, e0134529	22

204	A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9. 2016 , 11, e0145212		25
203	Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot. 2016 , 11, e0146710		17
202	Comparative Proteomics Reveals Important Viral-Host Interactions in HCV-Infected Human Liver Cells. 2016 , 11, e0147991		2
201	Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases. 2016 , 11, e0166763		12
200	HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes. 2017 , 12, e0166853		5
199	Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation. <i>PLoS Pathogens</i> , 2015 , 11, e1005183	7.6	18
198	The N-terminal Helical Region of the Hepatitis C Virus p7 Ion Channel Protein Is Critical for Infectious Virus Production. <i>PLoS Pathogens</i> , 2015 , 11, e1005297	7.6	14
197	Coordination of Hepatitis C Virus Assembly by Distinct Regulatory Regions in Nonstructural Protein 5A. <i>PLoS Pathogens</i> , 2016 , 12, e1005376	7.6	27
196	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. <i>PLoS Pathogens</i> , 2016 , 12, e1005568	7.6	20
195	Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. <i>PLoS Pathogens</i> , 2017 , 13, e1006232	7.6	11
194	NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains. <i>PLoS Pathogens</i> , 2017 , 13, e1006343	7.6	8
193	miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence. <i>PLoS Pathogens</i> , 2017 , 13, e1006694	7.6	18
192	A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism. <i>PLoS Pathogens</i> , 2018 , 14, e1006908	7.6	15
191	Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen. 2017 , 4, e16		5
190	[Way to the peptide vaccine against hepatitis C]. 2015 , 61, 254-64		2
189	Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation. 2016 , 7, 84575-84586		8
188	Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. 2014 , 8, 1-8		5
187	Hepatitis C virus Cell-to-cell Spread Assay. 2014 , 4,		4

186	[Production of infectious hepatitis C virus in cell culture]. 2005 , 55, 287-95	5
185	[Suppression of hepatitis C virus with the reagent targetting host factors]. 2008 , 58, 207-13	2
184	Advances in genomic research on hepatitis C virus with a useful tool, replicon system. 2008 , 57, 75-83	5
183	Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. 2008 , 14, 1670-81	30
182	Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. 2009 , 15, 240-4	12
181	Cell culture systems for the hepatitis C virus. 2007 , 13, 2442-5	15
180	Sequence diversity of hepatitis C virus: implications for immune control and therapy. 2007 , 13, 4808-17	72
179	Neutralizing antibodies in hepatitis C virus infection. 2007 , 13, 4824-30	36
178	Hepatitis C virus infection and apoptosis. 2007 , 13, 4865-72	104
177	Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics. 2010 , 16, 2100-8	3
176	Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. 2011 , 17, 2683-90	9
175	Entry of hepatitis C virus into the cell: a therapeutic target. 2012 , 18, 4481-5	8
174	Scotomas in molecular virology and epidemiology of hepatitis C virus. 2013 , 19, 7910-21	9
173	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. 2014 , 20, 2913-26	23
172	How hepatitis C virus invades hepatocytes: the mystery of viral entry. 2014 , 20, 3457-67	38
171	Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. 2015 , 21, 8492-507	20
170	Host restriction factors for hepatitis C virus. 2016 , 22, 1477-86	13
169	Cell culture-adaptive mutations in hepatitis C virus promote viral production by enhancing viral replication and release. 2018 , 24, 1299-1311	2

168	Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses. 2013 , 21, 97-106		15
167	SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016 , 22 Suppl, S25-57		15
166	Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression. 2014 , 3,		18
165	Roles of lipoprotein receptors in the entry of hepatitis C virus. 2015 , 7, 2535-42		6
164	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. 2015 , 7, 725-37		42
163	Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies. 2012 , 2, 7-25		2
162	Roles of the two distinct proteasome pathways in hepatitis C virus infection. 2012 , 1, 44-50		14
161	High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay. 2013 , 2, 18-31		8
160	A molecular tweezer antagonizes seminal amyloids and HIV infection. <i>ELife</i> , 2015 , 4,	8.9	55
159	Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus. <i>ELife</i> , 2019 , 8,	8.9	7
158	Hepatitis C virus exploits cyclophilin A to evade PKR. <i>ELife</i> , 2020 , 9,	8.9	8
157	Dengue virus is sensitive to inhibition prior to productive replication. 2021 , 37, 109801		1
156	In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?. 2021 , 13, 1234-1268		0
155	Chronic Hepatitis C. 2022 , 163-201		
154	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021 , 374, 1099-1106	33.3	7
153	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. 2021 , 12, 6105		3
152	Association of Hepatitis C Virus Replication with the Catecholamine Biosynthetic Pathway. 2021 , 13,		0
151	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. 2021 , 9,		0

- 150 Induction and Evasion of Innate Immunity by hepatitis C virus. **2006**, 47, 491-498 1
- 149 Complete Replication of Hepatitis C Virus in Cell Culture. **2007**, 2007, 354
- 148 Novel Approaches to Immunosuppression in Liver Transplantation. **2009**, 19-44
- 147 Proposition d'une nouvelle stratégie pour éviter la réinfection du greffon par le virus de l'hépatite C après transplantation hépatique. **2008**, 192, 1657-1668
- 146 Viral Phenotypic Resistance Assays. **2009**, 1187-1199
- 145 State-of-the-Art Lecture: Immune responses and viral escape mechanisms in hepatitis C virus infection. **2009**, 3-13
- 144 State-of-the-Art Lecture: Treatment of hepatitis C. **2009**, 105-119
- 143 HEPATITIS C VIRUS. **2009**, 2380-2394
- 142 Anti-HCV Agents in Development. **2009**, 159-183
- 141 Hepatitis C Virus. **2009**, 47-69
- 140 Hepatitis C virus immunology. **2009**, 14-21
- 139 Viral Hepatitis. **2010**, 315-327
- 138 Cell polarization and hepatitis C virus receptor-mediated cell entry. **2010**, 30, 892-895
- 137 Interferon Alfa. **2010**, 2959-2975
- 136 Detection of hepatitis C virus cross-neutralization antibodies in sera of hepatitis C patients. **2010**, 30, 1184-1188
- 135 Function of nonstructural 5A protein of genotype 2a in replication and infection of HCV with gene substitution. **2011**, 17, 3398-406 1
- 134 Hepatitis C Virus. **2011**, 1437-1455 1
- 133 Hepatitis C. 582-652

132 HCV and Blood Cells: How Can We Distinguish Infection from Association?. **2012**, 55-62

131 Mechanisms of Cell Entry of Hepatitis C Virus. **2012**, 63-68

130 HCV Replication. 1-11

129 Chronic Hepatitis in Childhood. **2012**, 2075-2093

128 Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. **2013**, 6, 161-170

10

127 Effect of Iron-Mediated Oxidative Stress on Insulin Resistance Through the Forkhead Box-Containing Protein O Subfamily-1 (FOXO-1) Pathway in Chronic Hepatitis C. **2013**, 04, 10-18

126 Update on the Development of Anti-Viral Agents Against Hepatitis C. **2013**, 1, 9-21

0

125 Phenotypic Susceptibility Assays for Human Immunodeficiency Virus Type 1. 283-299

124 Oxidative Stress in Chronic Viral Hepatitis. **2015**, 241-277

123 Molecular Mechanisms of Hepatitis C Virus Entry [Impact of Host Cell Factors for Initiation of Viral Infection. **2015**, 189-202

122 Cell Culture Systems for Propagation of HCV. **2016**, 67-80

121 Lipid Peroxidation and Hepatitis C Virus Replication. **2016**, 235-253

120 Innate Immune Recognition of Hepatitis C Virus. **2016**, 299-329

119 B Cell Responses and Control of HCV Infection. **2016**, 331-357

118 Novel Strategies for Immunizing Infants in Developing Countries Who Are Too Young to Receive the Currently Licensed Measles Vaccines. **2016**, 607-612

117 Viral Phenotypic Resistance Assays. **2017**, 1389-1407

1

116 A Polymorphic Residue That Attenuates the Antiviral Potential of Interferon Lambda 4 in Hominid Lineages.

1

115 A Polymorphic Residue That Attenuates Interferon Lambda 4 Activity in Hominid Lineages.

[illegible]

- 96 miR-122 affects both the initiation and maintenance of Hepatitis C Virus infections. 0
- 95 Chronic hepatitis C: Portrait of a silent epidemic and the etiologic agent. **2008**, 95-120
- 94 Mechanisms of Interferon Action and Resistance in Chronic Hepatitis C Virus Infection: Lessons Learned from Cell Culture Studies. **2008**, 16-38
- 93 Immunological Parameters Influencing Adaptive Immune Responses to the Hepatitis C Virus. **2008**, 39-70
- 92 New aspects of treatment of chronic hepatitis C. **2008**, 161-168
- 91 Immune Responses in Acute and Chronic Hepatitis C. **2007**, 193-208
- 90 A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy. **2020**, 47,
- 89 Retinoic Acid Inducible Gene-1 like Receptors Activate Snail and Slug to Limit RNA Viral Infections.
- 88 Medizin-Nobelpreis 2020 für die Entdeckung von Hepatitis C – Auftakt einer Erfolgsgeschichte in der Medizin. **2020**, 145, 1652-1653
- 87 An Entropic Safety Catch Controls Hepatitis C Virus Entry and Antibody Resistance. 1
- 86 Mathematical modeling of hepatitis C RNA replication, exosome secretion and virus release. **2020**, 16, e1008421 3
- 85 Extracellular Vesicles as Potential Therapeutic Targets and Biomarkers for Liver Disease. **2021**, 245-260
- 84 The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. **2007**, 9, 1-20 108
- 83 Overcoming hurdles in hepatitis C virus research: efficient production of infectious virus in cell culture. **2008**, 4, 82-8
- 82 Molecular and contextual markers of hepatitis C virus and drug abuse. **2009**, 13, 153-79 3
- 81 Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs. **2016**, 15, 578-588 3
- 80 New insights into HCV replication: potential antiviral targets. **2011**, 19, 117-20 58
- 79 Inhibitory activity of limonoids from *C. DC* (Meliaceae) against hepatitis C virus infection. **2021**, 11, 353-366

- 78 Longer Poly(U) Stretches in the 3'UTR Are Essential for Replication of the Hepatitis C Virus Genotype 4a Clone in and .. **2021**, 12, 764816 o
- 77 A Two-Level, Intramutant Spectrum Haplotype Profile of Hepatitis C Virus Revealed by Self-Organized Maps. **2021**, e0145921 2
- 76 Temporal control of the integrated stress response by a stochastic molecular switch.
- 75 Hepatitis C virus (HCV)-induced ROS/JNK signaling pathway activates the E3 ubiquitin ligase Itch to promote the release of HCV particles via polyubiquitylation of VPS4A.. **2022**, JVI0181121 o
- 74 Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.. **2022**, 1
- 73 Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.. **2022**, o
- 72 Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals.. **2022**, 103,
- 71 Antiviral DExD/H-box helicase 60 selectively inhibits translation from type II internal ribosome entry sites.
- 70 High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor.. **2022**, 10, o
- 69 miR-122 affects both the initiation and maintenance of Hepatitis C Virus infections.. **2021**, JVI0190321 2
- 68 NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a. **2021**, 67, E38-E47
- 67 Hepatocellular carcinomaAn updated review. **2022**, 11-31
- 66 Monitoring Virus-Induced Stress Granule Dynamics Using Long-Term Live-Cell Imaging.. **2022**, 2428, 325-348
- 65 The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection.. **2022**, e0199521 o
- 64 Temporal control of the integrated stress response by a stochastic molecular switch.. **2022**, 8, eabk2022 o
- 63 Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate.. **2022**, 119, e2112008119 o
- 62 Sequential Phosphorylation of Hepatitis C Virus NS5A Protein Requires the ATP-Binding Domain of NS3 Helicase.. **2022**, e0010722 o
- 61 A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo.

- 60 Protein tyrosine kinase Abl promotes hepatitis C virus particle assembly via interaction with viral substrate activator NS5A.. **2022**, 101804
- 59 In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture.. **2022**, 167501 o
- 58 A Role for B Cells to Transmit Hepatitis C Virus Infection.. **2021**, 12, 775098
- 57 High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system.. **2022**, 8, veab106 1
- 56 Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.. **2022**, o
- 55 Image_1.jpg. **2020**,
- 54 Image_2.jpg. **2020**,
- 53 Image_3.jpg. **2020**,
- 52 Image_4.jpg. **2020**,
- 51 Image_5.jpg. **2020**,
- 50 Data_Sheet_1.pdf. **2020**,
- 49 Image_1.pdf. **2018**,
- 48 Presentation_1.pdf. **2018**,
- 47 Image_1.TIF. **2020**,
- 46 Image_2.TIF. **2020**,
- 45 Image_3.TIF. **2020**,
- 44 Image_4.TIF. **2020**,
- 43 Image_5.TIF. **2020**,

42 Image_6.TIF. **2020**,

41 Image_7.TIF. **2020**,

40 Image_8.TIF. **2020**,

39 Table_1.XLS. **2020**,

38 Table_2.XLS. **2020**,

37 Table_3.XLS. **2020**,

36 Table_4.XLS. **2020**,

35 Table_5.XLS. **2020**,

34 Table_6.XLS. **2020**,

33 Table_7.XLS. **2020**,

32 Table_8.XLS. **2020**,

31 Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis.. *Biomedicine and Pharmacotherapy*, **2022**, 150, 113024 7.5

30 Modulation of Zika virus replication via glycosphingolipids.. *Virology*, **2022**, 572, 17-27 3.6

29 Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection. *Antiviral Therapy*, **2006**, 11, 273-287 1.6 7

28 Genomics of Hepatitis B and C Infections: Diagnostic and Therapeutic Applications of Microarray Profiling. *Antiviral Therapy*, **2006**, 11, 541-552 1.6 5

27 A human and rhesus macaque interferon-stimulated gene screen reveals ARHGEF3/XPLN as an antiviral gene against hepatitis C virus and other flaviviruses.

26 A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo. *PLoS Pathogens*, **2022**, 18, e1010472 7.6 0

25 Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. *JCI Insight*, **2022**, 7, 9.9 1

- 24 An entropic safety catch controls Hepatitis C virus entry and antibody resistance. *ELife*, 11, 8.9 o
- 23 Hepatitis C virus NS5A protein promotes the lysosomal degradation of diacylglycerol O-acyltransferase 1 (DGAT1) via endosomal microautophagy. **2022**, 1, 264-285
- 22 Natural reservoirs of viruses of the genus <i>Hepacivirus</i>, Flaviviridae. **2016**, 61, 101-106
- 21 A Human and Rhesus Macaque Interferon-Stimulated Gene Screen Shows That Over-Expression of ARHGEF3/XPLN Inhibits Replication of Hepatitis C Virus and Other Flavivirids. **2022**, 14, 1655 o
- 20 Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture. 13,
- 19 Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. *gutjnl*-2021-326323 o
- 18 Identification of novel neutralizing determinants for protection against hepatitis C virus. o
- 17 Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants. **2022**, 17, e0274283 o
- 16 Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C. **2022**, 13, o
- 15 Barriers to hepatitis C virus infection in mice. **2022**, 56, 101273 1
- 14 DDX60 selectively reduces translation off viral type II internal ribosome entry sites. o
- 13 Characterization of a multipurpose NS3 surface patch coordinating HCV replicase assembly and virion morphogenesis. **2022**, 18, e1010895 o
- 12 Hepatitis B Virus X Protein Stimulates Hepatitis C Virus (HCV) Replication by Protecting HCV Core Protein from E6AP-Mediated Proteasomal Degradation. o
- 11 Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization. **2022**, 14, 2527 o
- 10 Plasma-Like Culture Medium for the Study of Viruses. o
- 9 Occult hepatitis C infection: viruses with infectious potential in Huh7.5 and MDBK cell lines suggest HCV/OCI transmission. **2023**, 11, 1-8 o
- 8 Hepatitis C virus and hepatocellular carcinoma. **2023**, 243-262 o
- 7 Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. 2207875 o

- 6 Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412025 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles. ○
- 5 The role of human lipoproteins for hepatitis C virus persistence. **2023**, 60, 101327 ○
- 4 Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response. **2023**, 15, 464 ○
- 3 Hepatitis C virus fitness can influence the extent of infection-mediated epigenetic modifications in the host cells. 13, ○
- 2 Elucidating the distinct contributions of miR-122 in the HCV life cycle reveals insights into virion assembly. **2023**, 51, 2447-2463 ○
- 1 Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus. **2023**, 15, 981 ○